Protocol : J2X-MC-PYAH 
 
A Randomized, Double -blind, Placebo- Controlled, Phase 2 Study to Evaluate the Efficacy and  
Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild  
to Moderate COVID -19 Illness (BLAZE -4) 
[STUDY_ID_REMOVED] 
Approval Date: 18- May-2021 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of LY3819253 ,LY3832479 , LY3853113 ,and VIR -7831 unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information A ct (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title:
A Rando mized, Double -blind, Pl acebo -Controlled, Phase 2 Study  to Eval uate the Efficacy  and
Safety of Mono and Combinat ion Therapy with Monocl onal Ant ibodies in Participants with Mild 
to Moderate COVID -19 Illness (BLAZE -4)
Protocol Number: J2X-MC-PYAH
Amendment Number: g
Compound(s): LY3819253, LY 3832479 , LY3853113 ,VIR-7831
Study Phase: 2
Short Title: A rando mized, double -blind, pl acebo -controlled, Phase 2 study  to eval uate 
combinat ions of monoclonal antibodies in part icipants wi th mild to m oderate 
COVID -19 illness
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana ,USA 46285
Regulatory Agency Identifier Number(s)
IND: 150440
Approval Date: Protocol Amendment ( g) Electronically Signed and Approved by Lilly ondate 
provi ded below.
Approval Date: 18-May-2021 GMT
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
2Medical Monitor Name and Contact Information will be provided separately 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment f 16 Mar 2021
Amendment e 25 Jan 2021
Amendment d 15 Jan 2021
Amendment c 06 Jan 2021
Amendment b 03 Dec 2020
Amendment a 16 Oct 2020
Original Protocol 5 Oct 2020
Amendment g
Overall Rationale for the Amendment:
The purpose of this amendment isto incorporate a new treatment arm into the study  design. 
Addit ionally , minor clarificat ions and edits were made for operational efficiency  and 
consistency.
Section # and Name Description of Change Brief Rationale
1.1 Synopsis ; 1.2 Schema ; 1.3 Schedule of 
Activities; 3.4 Treatment Arms 12 -14;4.1 
Overall Design; 4.2 Scientific Rationale for 
Study Design; 4.3 Justification for Dose;
6.1 Study Intervention(s) Administered; 6.3 
Measure to Minimize Bias: Randomization 
and Blinding; 9.2 Sample Size 
Determination; 9.4Statistical Analyses; 
9.4.2 Primary EndpointsAdded treatment arm 14 to 
study designAllowance of additional high -
risk participants in triplet 
combinatio n cohor t
2.2 Background Updated LY3853113 
pseudovirus assay informationAlignment with Investigator’s 
Brochure
5.1 Inclusion Criteria Specified that criteria 27 and 28 
are applicable to treatment arms 
12 and 13 onlyDifferentiation of high -risk 
participants applicable for 
treatment arms 12 and 13 and 
treatment arm 14
5.1 Inclusion Criteria Added new inclusion criterion 
30 for treatment arm 14Differentiation of high -risk 
participants applicable for 
treatment arms 12 and 13 and 
treatment arm 14
5.2 Exclusion Criteria Specified in exclusio n criterion 
22that participation in previous 
SARS -CoV -2 vaccine study is 
excluded if participant has 
received a SARS -CoV-2 
vaccine or is currently blinded 
to treatment allotmentClarification
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
4Section # and Name Description of Change Brief Rationale
6.1 Study Intervention(s) Admi nistered;
8.2.2 Vital SignsRem oved instructio ns for 
multiple administration sin 
treatment arms 9 -14Arms 9 -14 will not utilize 
multiple administrations
ThroughoutMinor editorial and formatting 
changesMinor, therefore not detailed
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
5Table of Contents
1. Protocol Summary ................................ ................................ ................................ ......8
Synopsis ................................ ................................ ................................ ....................... 8
Schema ................................ ................................ ................................ ....................... 17
Schedule of Act ivities (SoA) ................................ ................................ ...................... 18
1.3.1. Treatment Arms 1 -6................................ ................................ ................................ ....18
1.3.2. Treatment arms 7 -8................................ ................................ ................................ .....27
1.3.3. Treatment Arms 9 -14................................ ................................ ................................ ..37
2. Introduction ................................ ................................ ................................ .............. 45
Study  Rati onale ................................ ................................ ................................ .......... 45
Background ................................ ................................ ................................ ................ 45
Benefit/Risk Assessment ................................ ................................ ............................ 48
3. Objectives and Endpoints ................................ ................................ ......................... 50
Treatment Arms 1 -6................................ ................................ ................................ ....50
Treatment Arms 7 -8................................ ................................ ................................ ....51
Treatment Arms 9 -11................................ ................................ ................................ ..53
Treatment Arms 12 -14................................ ................................ ................................ 54
4. Study Design ................................ ................................ ................................ ............. 56
Overall Design ................................ ................................ ................................ ............ 56
4.1.1. Design Outline ................................ ................................ ................................ ............ 56
Scientific Rationale for Study Design ................................ ................................ ......... 58
Justification for Dose ................................ ................................ ................................ ..59
End of Study  Defini tion................................ ................................ .............................. 60
5. Study Population ................................ ................................ ................................ ......61
Inclusio nCriteria................................ ................................ ................................ ........ 61
Exclusio n Cri teria................................ ................................ ................................ ....... 63
Lifest yle Considerat ions................................ ................................ ............................. 64
Screen Failures ................................ ................................ ................................ ........... 64
6. Study Int ervention ................................ ................................ ................................ ....65
Study  Intervent ion(s) Administered ................................ ................................ ............ 65
6.1.1. Speci al Treatm ent Consi derat ions................................ ................................ ............... 67
6.1.2. Temporary  Stopping Cri teria................................ ................................ ...................... 68
Preparati on/Handling/Storage/Accountabilit y................................ ............................. 69
Measures to Minimize Bias: Rando mizat ion and Blinding ................................ .......... 69
Study  Intervent ion Compliance ................................ ................................ ................... 71
Concomitant Therapy ................................ ................................ ................................ .71
Dose Modificat ion................................ ................................ ................................ ......72
Intervention after the End of the Study ................................ ................................ ........ 72
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ .................... 73
Discontinuati on of  Study  Intervent ion................................ ................................ ........ 73
Parti cipant Discontinuati on/Wi thdrawal from  the Study ................................ ............. 73
7.2.1. Discontinuati on of  Inad vertent ly Enrolled Participants ................................ ............... 73
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
6
Lost to Follow up ................................ ................................ ................................ ....... 74
8. Study Assessments and Procedures ................................ ................................ ......... 75
Efficacy Assessments ................................ ................................ ................................ .75
8.1.1. Symptom s and Overall Clinical Status Participant Quest ionnaire ................................ 75
Safety Assessments ................................ ................................ ................................ ....76
8.2.1. Physical Examinat ions................................ ................................ ................................ 76
8.2.2. Vital Signs................................ ................................ ................................ .................. 76
8.2.3. Clinical Laboratory  Assessments ................................ ................................ ................ 77
8.2.4. Hospi talizati on events ................................ ................................ ................................ .78
8.2.5. Procedures of Special Interest ................................ ................................ ..................... 78
8.2.6. Respiratory  Support ................................ ................................ ................................ ....79
Adverse Events and Serious Adverse Events ................................ .............................. 79
8.3.1. Time Period and Frequency for Collect ing AE and SAE 
Inform ation................................ ................................ ................................ ................. 79
8.3.2. Method of Detecting AEs and SAEs ................................ ................................ ........... 80
8.3.3. Follow-up of  AEs and SAEs ................................ ................................ ....................... 80
8.3.4. Regulatory  Reporting Requi rements for SAEs ................................ ............................ 80
8.3.5. Pregnancy ................................ ................................ ................................ ................... 80
8.3.6. Hypersensi tivity Reactions................................ ................................ ......................... 80
8.3.7. Infusio n-related Reacti ons................................ ................................ .......................... 81
8.3.8. Product Complaint s................................ ................................ ................................ ....81
Treatment of Overdose ................................ ................................ ............................... 82
Pharmacokinet ics................................ ................................ ................................ ........ 82
8.5.1. Bioanaly tical................................ ................................ ................................ .............. 83
Pharmacodynamics ................................ ................................ ................................ .....83
Genet ics................................ ................................ ................................ ..................... 83
Biomarkers ................................ ................................ ................................ ................. 83
Immunogenici ty Assessments ................................ ................................ ..................... 84
Health Economics ................................ ................................ ................................ ....... 84
9. Statistical Considerations ................................ ................................ ......................... 85
Statistical Hypotheses ................................ ................................ ................................ .85
Sample Si ze Determinat ion................................ ................................ ......................... 85
Popul ations for Analyses ................................ ................................ ............................ 87
Statistical Analyses ................................ ................................ ................................ .....87
9.4.1. General Considerations ................................ ................................ ............................... 88
9.4.2. Primary Endpo ints................................ ................................ ................................ ......88
9.4.3. Secondary  Endpo ints................................ ................................ ................................ ..88
9.4.4. Exploratory  Analyses ................................ ................................ ................................ ..90
9.4.5. Immunogenici ty Analyses ................................ ................................ ........................... 90
9.4.6. Subgroup Analyses ................................ ................................ ................................ .....91
Interim Analyses ................................ ................................ ................................ ......... 91
Data Monitoring Committee (DMC) ................................ ................................ ........... 93
10. Supporting Documentation and Operational Considerations ................................ 94
Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ................................ ................................ ................................ ............ 94
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
710.1.1. Regulatory  and Ethi cal Considerat ions................................ ................................ ........ 94
10.1.2. Financial Disclo sure................................ ................................ ................................ ...94
10.1.3. Inform ed Consent Process ................................ ................................ .......................... 95
10.1.4. Data Protection ................................ ................................ ................................ ........... 95
10.1.5. Committees Structure ................................ ................................ ................................ .96
10.1.6. Disseminat ion of Clinical Study  Data ................................ ................................ ......... 96
10.1.7. Data Qualit y Assurance ................................ ................................ .............................. 96
10.1.8. Source Documents ................................ ................................ ................................ ......97
10.1.9. Study  and Si te Start and Cl osure ................................ ................................ ................. 98
10.1.10. Publicat ion Policy ................................ ................................ ................................ ....... 98
10.1.11. Invest igator Informat ion................................ ................................ ............................. 98
10.1.12. Long -Term  Sample Retent ion................................ ................................ ..................... 99
Appendix 2: Clinical Laboratory  Tests ................................ ................................ ......100
Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ................................ ..................... 103
10.3.1. Definit ion of AE................................ ................................ ................................ ....... 103
10.3.2. Definition of SAE ................................ ................................ ................................ .....104
10.3.3. Recording and Fo llow-Up of  AE and/or SAE ................................ ........................... 105
10.3.4. Reporting of SAEs ................................ ................................ ................................ ....107
Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ................................ ................................ ............................. 108
Appendix 5: Genetics ................................ ................................ ............................... 111
Appendix 6: Reco mmended Laboratory Test ing for 
Hypersensi tivity Events. ................................ ................................ ........................... 112
Appendix 7: Liver Safet y: Suggested Actions and Fo llow-up 
Assessments ................................ ................................ ................................ ............. 114
Appendix 8: Abbreviat ions................................ ................................ ....................... 118
Appendix 9: Protocol Amendment History ................................ ............................... 120
11. References ................................ ................................ ................................ ............... 126
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
81. Protocol Summar y
Synopsis
Protocol Title:
A Rando mized, Double -blind, Pl acebo -Controlled, Phase 2 Study  to Eval uate the Efficacy  and 
Safety of Mono and Combinat ion Therapy with Monoclonal Antibodies in Participants with Mild 
to Moderate COVID -19 Illness (BLAZE -4)
Rationale:
The severe acute respiratory  syndrome coronavirus 2 (SARS -CoV -2) has resulted in the 
pandemic spread of coronavirus disease 2019 (COVID -19), which in crit ical cases res ults in 
progressive pulmo nary failure, com plicati ons wi th acute respi ratory  distress syndrome (ARDS), 
and death. There is an urgent need for effect ive therapeutics to modify disease outcomes.
LY3819253 ,LY3832479 , and LY3853113 are neutralizing IgG1 monoclonal ant ibodies (mAb) 
to the spike protein of SARS -CoV -2. They  are designed to block viral attachment and entry  into 
human cells, and to neutralize the virus, potentially treating even established COVID -19 by  
provi ding a co mbinat ion of specific, pote nt, neutralizing antibodies to SARS -CoV -2. 
VIR-7831 is a human IgG1 mAb that binds to the spike protein of SARS -CoV -2. It contains 
modificati ons to enhance both respi ratory  mucosal distribut ion and the half -life. An increased 
distribut ion to mucosal tissu eis expected to result in higher and more sustained levels o f VIR-
7831 in the respiratory  mucosa, whi ch is a potenti al advantage for treatment and prophylaxis.
The aim of the st udyisto evaluate the impact of LY3819253 alone, LY3853113 al one,
LY3819253 + LY3832479 , LY3853113+ LY3819253 + LY3832479 , and LY3819253 + VIR -
7831 on viral  clearance and clinical outcomes in participants with COVID -19 illness. 
Addit ionally, the study  aims to character ize the safety  profile of LY3853113 alo ne and in 
combinat ion with LY3819253 and LY3832479 in participants at high risk of developing severe 
COVID -19 illness . The data from this study  will inform  decisi ons f or the clinical development of 
LY3819253 ,LY3832479 , LY3853113 ,and VIR -7831 . 
Objectives and Endpoints:
Treatm ent Arms 1 -6:
Primary
Characterize the effect of LY3819253 alone and in 
combinatio n with LY3832479, compared to placebo on 
SARS -CoV -2 viral load Proportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7 (+2 days)
Secondary
The secondary objectives are to characterize the effect 
of LY3819253 alone and in combination with 
LY3832479, compared to placebo on…
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
9overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 29
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
oDay 7 (±2 day s)
oDay 11 (±2 day s)
Proportio n of participants with viral load grea ter 
than 5.27 on Day 7 (+2 days) among participants 
enrolled with ≤8 days of symptoms prior to 
randomization 
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11 , and 29 )
Time to SARS -CoV-2 clearance 
SARS -CoV -2 viral load area u nder the response -
time curve (AUC) assessed through Day 11
symptom resolution Time to symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
3, 5, 7, 11 , 22, and 29
Change in symptom score (total of ratings) from 
baseline up to Day s 7,11, 22, and 29 . 
AUC from baseline to Day 11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 3, 5, 7, 11 , 22,and 29
safety Safety assessments such as AEs and SAEs
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22,60,and 85
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 29: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care)
oCOVID -19 related emergency room visit, or
odeath 
characterize the pharmacokinetics of LY3819253 
and LY3832479Mean concentration of LY3819253 and 
LY3832479 on Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2. 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
10Treatment Arms 7-8:
Primary
Characterize the effect of LY3819253 in combination 
with VIR-7831 , compared to placebo on SARS -CoV-2 
viral load Proportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7 (+2 days)
Secondary
The secondary objectives are to characterize the effect 
of LY3819253 in combination with VIR-7831 , 
compared to placebo on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 29
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
oDay 7 (±2 day s)
oDay 11 (±2 day s)
Proportio n of participants with viral load greater 
than 5.27 on Day 7 (+2 days) among participants 
enrolled with ≤8 days of symptoms prior to 
randomization 
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11, and 29)
Time to SAR S-CoV-2 clearance 
SARS -CoV -2 viral load AUC assessed through 
Day 11
symptom resolution Time to symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
3, 5, 7, 11, 22, and 29
Change in symptom score (total of ratings) from 
baseline up to Days 7, 11, 22, and 29. 
AUC from baseline to Day 11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 3, 5, 7, 11, 22, and 29
safety Safety assessments such as AEs and SAEs
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22, 60 ,and 85
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
11characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 29: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care)
oCOVID -19 related emergency room visit, or
odeath 
characterize the pharmacokinetics of LY3819253 
and VIR-7831Mean concentration of LY3819253 and VIR-7831
on Day  29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2. 
Treatment Arms 9-11:
Primary
Characterize the effect of LY3853113 alone and in 
combinatio n with LY3819253 and LY3832479 after 
intravenous infusion compared to placebo on SARS -
CoV-2 viral loadProportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7
Secondary
The secondary objectives are to c haracterize the effect 
of LY3853113 alone and in combination with 
LY3819253 and LY3832479 after intravenous infusion 
compared to placebo on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 2 9
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2viral load and viral clearance 75thPercentile of SARS -CoV -2 viral load at Day 7
Change f rom baseline to 
oDay 3
oDay 5
oDay 7
oDay 11
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11 , and 29)
Time to SARS -CoV-2 clearance 
SARS -CoV-2 viral load area under the response -
time curve (AUC) assessed through Day 11
symptom resolution Time to symptom resolution 
Time to sustained symptom resolution
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
2-11, 22, and 29
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
12symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire o n 
Days 2-11, 22, and 29
safety Safety assessments such as AEs and SAEs
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 22
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
Characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 2 9: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care),
oCOVID -19 related emergency room visit, or
odeath 
Characterize the pharmacokinetics of LY3853113 , 
LY3819253, and LY 3832479Mean concentration of LY3853113 , LY3819253, 
and LY3832479 on Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2 .
Treatment Arms 12 -14:
Primary
Characterize the safety profile of LY3853113 alone 
and in combination with LY3819253 and LY3832479 
after intravenous infusion on SARS -CoV-2 viral loadSafety assessments such as AEs and SAEs
Secondary
The secondary objectives are to c haracterize the effect 
of LY3853113 alone and in combination with 
LY3819 253 and LY3832479 after intravenous infusion 
on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 2 9
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance 75thPercentile of SARS -CoV -2 viral load at Day 7
Change f rom baseline to 
oDay 3
oDay 5
oDay 7
oDay 11
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11 , and 29)
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
13Time to SARS -CoV-2 clearance 
SARS -CoV -2 viral load area under the response -
time curve (AUC) assessed through Day 11
Proportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7
symptom resolution Time to symptom resolution 
Time to sustained symptom resolution
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
2-11, 22, and 29
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2-11, 22, and 29
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 22
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
Characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 2 9: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care),
oCOVID -19 related emergency room visit, or
odeath 
Characterize the pharmacokinetics of LY3853113 , 
LY3819253, and LY3832479Mean concentration of LY3853113 , LY3819253, 
and LY3832479 on Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2 .
Overall Design:
This is a Phase 2, randomized, single -dose study  in parti cipants wi th mild to m oderate COVID -
19 illness. Treatm ent a rms 1-11 are double -blind and placebo controlled, and treatm ent a rms 12-
14are open label.
Design Outline
Screening
Interested participants will sign the appropriate informed consent and child/ado lescent assent 
docum ent(s) , as appropriate, prior to complet ion of any  procedures. 
The invest igator will review symptoms, risk factors and other non -invasive inclusio n and 
exclusio n criteria pri or to any  invasive procedures. If the participant is eligible after this review, 
then the site will perf orm the invasive procedures to confirm eligibilit y. 
Double -blind Treatment and Assessment Period
This is the general sequence of events during the treatment and assessment period:
Com plete baseline procedures and sample collect ion
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
14Parti cipants are randomi zed to an intervent ion group 
Parti cipants receive study  intervent ion, and
Com plete all  safety  monitoring and post -treatment sample collect ion. 
This table describes the visit and act ivity types for thi s study .
Study Day Activity Visit Type
1 Follow SoA Site 
2, 4, 6, and 22 Follow SoA Telepho ne visit 
3, 5, 7, 11, 29, ED, 60, and 85 Follow SoA May be conducted as outpatient 
clinic or home visit. Symptom 
assessments can be collected 
via telephone visit. 
8, 9, 10 Collection of symptom assessments Telep hone visit
Early  discontinuation and follow -up Follow SoA May be conducted as outpatient 
clinic or home visit
169 (Arms 7 and 8 only) AE/SAE collection , concomitant 
medicationsTelepho ne visit
Abbreviations: SoA = schedule of activities
If a participant is hospi talized, procedures and assessments will cont inue per the SoA
(Secti on1.3). 
This table describes discharge fro m hospi tal scenari os if an outpati ent is subsequent ly 
hospi talized.
Discharge from hospital (Outpatients Subsequently Hospitalized)
If hospital discharge… Then…
Occurs prior to Day 29 participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA (Section 1.3). 
NOTE: Strategies to manage infection risks and reduce 
the burden of return visits should be used by sites, such 
as home visits.
Occurs on the same day as a study assessment visit assessments do not need to be repeated if the study 
assessments occurred within 8 hours of discharge and 
there has been no change in clinical status and the 
information is available to the site.
Does not occur at or prior to Day 29 assessments will contin ue to occur weekly up to Day 
60 or until hospital discharge, whichever is sooner.
Abbreviations: S oA = schedule of activities
Post-treatment follow -up
Post-treatm ent follow-up assessments will be conducted at Day  60 and Day  85 to assess clinical 
status a nd for adverse events. Strategies to manage infect ion risks and reduce the burden o f 
return visits may be used by sites, such as ho me visits. For Arms 7 and 8, an addit ional telephone 
visit will occur on Day  169 to assess for occurrence of any safet y conce rns.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
15Disclosure Statement : This is a treatm ent study  that i s parti cipant and invest igator blinded , 
unless noted otherwise . 
Number of Participant s:
Treatment arms 1 -6
The init ial planned sample size is a pproximately 500 participants allocated across five treatm ent 
arms(treatm ent arms 1 through 5) .The pl anned sample size is approximately 100 participants 
for treatm ent arm  6. Since treatm ent arm  6 begins enrollment after treatment arms 1 -5, addi tional 
participants will be enrolled in treatment arm 1 to ens ure at l east a 50% increase in placebo 
participants and concurrent placebo control for the primary  com parison of treatment arm 6. 
Addit ional participants will also be enro lled in treatment arm 3 to ensure at least a 50% increase 
in LY3819253 700 mg + LY383 2479 1400 m g parti cipants to provi de concurrent enrollment of 
an addit ional treatment arm.
Up to 100 additional participants may  be introduced ei ther for each opti onal treatm ent arm or in
addition to an exist ing treatment arm (including placebo) . See Sect ion 9.5for interim analysis 
details.
Treatment arms 7 -8
The pl anned sam ple size is approximately  100 participants per treatm ent arm . 
Treatment arms 9-11
The pl anned sam ple size is approximately  122participants per treatment arm.
Treatment arms 12 -14
Approximately  100 parti cipants will be enrolled into treatm entarm 12 and approximately 50 
participants will be enrolled into treatm ent arm 13 .Approximately 140 participants will be 
enrolled into treatment arm 14 once treatm ent arms 12 and 13 have co mpleted enrollment.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
16Intervention Groups and Duration: 
This table describes the planned treatment arms. 
Treatment 
armsDose Intervention Participant 
Population
1 --- Placebo ---
2 175 mg + 350 mg LY3819253 +LY3832479 ---
3 700 mg + 1400 mg LY3819253 +LY3832479 ---
4 2800 mg + 2800 mg LY3819253 +LY3832479 ---
5 700 mg LY3819253 ---
6 350 mg + 700 mg LY3819253 +LY3832479 ---
7 700 mg + 500 mg LY3819253 +VIR-7831 ---
8 --- Placebo ---
9 175 mg LY3853113 Low risk
10 175 mg + 700mg + 1400 mg LY3853113 + LY3819253 +LY383247 9 Low risk
11 --- Placebo Low risk
12 175 mg LY3853113 High riska
13 175 mg + 700mg + 1400 mg LY3853113 + LY3819253 + LY3832479 High riska
14 175 mg + 700 mg + 1400 mg LY3853113 + LY3819253 + LY3832479 High riskb
aSee Section 5.1, Inclusion C riteria 27 and 28 for definition of high -riskparticipants applicable for treatment arms 
12 and 13
bSee Section 5.1, Inclusion Criterion 30 for definition of high -risk participants applicable for treatment arm 14
Treatment arm 1 is the corresponding placebo control for treatm ent arm s 2-4 and 6.
Treatment arm 8is the corresponding placebo control for treatm ent arm  7.
Treatment arm 11is the corresponding placebo control for treatment arms 9and 10.
Optional treatm ent arm s may be added based on interim analysis results and/orother emerging 
data. 
Parti cipants will receive a single treatm ent on Day  1, assessments occur to Day  29 and fo llow-up 
to Day  85for Arms 1 -6, 9-14, and Day 169 for Arms 7 -8.
Data Monitoring Committee: Yes, there will be an assessment committee.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
17
Schema
aSee Section 5.1, Inclusion Criteria 27 and 28 for definition of high -riskparticipants applicable for treatment arms 
12 and 13
bSee Section 5.1, Inclusion Criterion 30 for definition of high -riskparticipants applicable for treatment arm 14
Note: Additional arms may be added based on interim analysis results and other emerging data.
Abbreviations: LY = Lilly study intervention.
Figure 1. Study J2X-MC-PYAH schema

CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
18
Schedule of Activities (SoA)
Assessments obtained previously  as part of routine clinical care may  be used as the baseline assessment if they were done no more 
than 48 hours before rando mization. Vi sits may  be conducted as a telephone call, outpatient clinic or home visit, as long as the 
protocol  SoA is fo llowed. Refer to the study  day and visi t type table in Sect ion 4.1.1 for addi tional clarification.
1.3.1. Treatment Arms 1 -6
This SoA i sfor parti cipants in Treatm ent Arms 1through 6.
Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Informed consent X
Inclusion and 
exclusion criteria 
reviewX
Demographics X Including age, gender, race, ethnicity 
Preexisting 
conditio ns and 
medical historyXObtained from interview or available 
information.
Includes: risk factors and comorbidities 
associated with severe COVID -19 illness, such 
as living in a nursing home or long -term care 
facility. 
Prespecified 
medical history: 
COVID -19XIncludes COVID -19 diagnosis date and onset 
of COVID -19 symptoms.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
19Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Height X
Weight X
Prior treatments 
of special interest 
within the last 30 
daysXNSAIDs, antivirals, antibiotics, anti -malarials, 
corticosteroids, immunomodulators or other 
investigational treatments.
Substance use 
(tobacco)XIncludes use of e -cigarettes, such as vaping
Concomitant 
medicationsX X X X X X X X X X X X X X X
Adverse events 
(AEs)X X X X X X X X X X X X X X XAny events that occur after signing the 
informed consent are considered AEs as 
defined in Section 10.3.
Additional details regarding reporting 
frequency  and method of detecting AEs 
and SAEs can be found in Section 8.3.
Physical Evaluation or Clinical Assessments
Physical 
examinationX
Symptom -directed 
physical examX X XAs indicated based on participant status 
and standard of care. May be performed 
by qualified personnel per local 
regulations.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
20Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Vital signs and 
oxygen supportX X X X X X X X X X XDocumentation of hospital -based exam is 
acceptable.
Includes: body temperature, pulse rate, 
BP, respiratory rate, SpO2, and 
supplemental oxygen flow rate, FiO2 if 
known, method of delivery, if applicable, 
and oxygen support procedures. 
Record SpO2 while participant is at rest.
Screening visit only : SpO2 wh ile 
breathing room air. Data not collected on 
CRF.
Day 1 timing:
immediately before administration
every 15 minutes during the infusion, 
as possible and applicable, and
every 30 minutes for 1 hour after the 
administration. 
During infusion, only record pu lse rate, 
BP and SpO2. Automation may be used. 
See Section 8.2.2 for data collected on 
CRF.
All other study days: once daily. 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
21Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Hospitalization 
eventsDaily X X X X X XRecord if the following events occur or 
occurred since prior visit:
Emergency room visits
Hospitalized
ICU admittance
Extended care facility admittance, 
and
Discharge
Clinical status and 
concomitant 
procedures if 
participant is 
hospitalizedDaily  if hospitalized X X X XDocumentation from hospital records is 
acceptable if hospitalized at any time.
Includes the following:
NEWS 2 Consciousness (ACVPU)
Limitation on activities due to 
COVID -19 (Patient Global 
Assessment for Daily Activities of 
Physical Function)
Concomitant procedures of interest 
for organ support (e.g., proning, renal 
support)
Additional organ support (e.g. ,pressors, 
renal replacement). Oxygen support and 
vital signs data should be collected while 
participant is hospitalized.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
22Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Laboratory Tests and Sample Collection
Hematology X X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Clinical chemistry X X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day
No samples needed if participant is 
hospitalized 
Lilly -designated central laboratory
C-reactive protein 
(CRP); high -
sensitivity X X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day 
No sample needed if participant is hospitalized
Lilly -designated central laboratory
Ferritin X X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day 
No sample needed if participant is hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
23Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
D-dimer X X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day 
No sample needed if participant is hospitalized
Lilly -designated central laboratory
Procalcitonin X X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day 
No sample needed if participant is hospitalized
Lilly -designated central laboratory
Troponin I and 
Troponin TX X X X XDay 1: before treatment administration
All other days: sample may occur at any time 
during the day 
No sample needed if participant is hospitalized
Lilly -designated central laboratory
Documentation of 
positive SARS -
CoV-2 viral 
infection XSample for first positive test must be collected 
within 3 days prior to start of infusion. 
Local laboratory and/or Point -of-Care testing.
Urine or serum 
pregnancy X X XOnly for WOCBP (Section 10.4,Appendix 4) 
Local laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
24Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Pharmacokinetic 
(PK) sample
for
LY3819253
LY3832479X X X X X XDay 1: no pre -dose sample needed; one post -
dose sample within 30 minutes after the end of 
infusion (may include the flush). 
All other scheduled samples may occur at any 
time during the day.
No samples needed if participant is 
hospitalized.
Lilly -designated central laboratory 
Immunogenicity 
(ADA) sample for
LY3819253
LY3832479X X X X X XDay 1: collect before treatment administration. 
All other scheduled and unscheduled 
immunogenicity samples should be collected 
with a time -matched PK sample.
No samples needed if participant is 
hospitalized .
Lilly -designated central laboratory
Pharmacodynamic 
(PD) NP swab X X X X X X XSwab is taken from both nostrils. 
Day 1: swab before treatment administration.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Explo ratory  
biomarker 
samplesX X X X X X Day 1: before treatment administration.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
25Schedule of Activities for Treatment Arms 1-6
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on 
the same day.
* = telephone visit(s) for all treatment arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Explo ratory  
serum sampleX X
Pharmacogenetics 
sampleX Lilly -designated central laboratory
Randomization and Dosing
Randomization X
Administer study 
interventio nXStudy  intervention must be administered 
within 3 days from the time of first positive 
SARS -CoV -2 test sample collection.
For participants that receive dialysis on the 
same day as administration of study 
intervention, complete dialysis first followed 
by the study treatment.
Participants will be monitored for at least 1 
hour after completion of treatment 
administration. 
Participant Questionnaire
Symptoms 
(patient symptom 
assessment) and 
overall clinical 
statusDaily  on Day s 1-11 for outpatients only X X X X X Day 1: assess prior to dosing
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
26Abbreviations: ACVPU = alert, consciousness, verbal, pain, unresponsive scale; ADA = anti -drug antibody; AEs = adverse events; BP = blood pressure; CRF = 
case report form; ED = early discontinuation visit; FiO2 = fraction of inspired oxygen in the air; ICU = intensive care unit; NP = nasopharynge al; NSAID s= 
non-steroidal anti -inflammatory drugs; SAEs = serious adverse events; SARS -CoV-2 = severe acut e respiratory syndrome coronavirus 2 ; SpO2 = saturation 
of peripheral oxygen; WOCBP = women of child -bearing potential. 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
271.3.2. Treatment arms 7 -8
This SoA i s for parti cipants in Treatm ent Arms 7and 8 . 
Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Procedures
Informed consent X
Inclusion and 
exclusion criteria 
reviewX
Demographics X Including age, gender, race, ethnicity 
Preexisting 
conditio ns and 
medical historyXObtained from interview or available 
information.
Includes: risk factors and comorbidities 
associated with severe COVID -19 
illness, such as living in a nursing home 
or long -term care facility. 
Prespecified 
medical history: 
COVID -19XIncludes COVID -19 diagnosis date and 
onset of COVID -19 sy mptoms.
Height X
Weight X
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
28Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Prior treatments 
of special interest 
within the last 30 
daysXNSAIDs, antivirals, antibiotics, anti -
malarials, corticosteroids, 
immunomodulators or other 
investigational treatments.
Substance use 
(tobacco)XIncludes use of e -cigarettes, such as 
vaping
Concomitant 
medicationsX X X X X X X X X X X X X X X X
Adverse events 
(AEs)X X X X X X X X X X X X X X X XAny events that occur after signing 
the informed consent are considered 
AEs as defined in Section 10.3.
Additional details regarding 
reporting frequency and method of 
detecting AEs and SAEs can be 
found in Section 8.3.
Physical Evaluation or Clinical Assessments
Physical 
examinationX
Symptom -directed 
physical examX X XAs indicated based on participant 
status and standard of care. May be 
performed by qualified personnel 
per local regulations.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
29Vital signs and 
oxygen supportX X X X X X X X X X XDocumentation of hospital -based 
exam is acceptable.
Includes: body temperature, pulse 
rate, BP, respiratory rate, SpO2, and 
supplemental oxygen flow rate, 
FiO2 if known, method of delivery, 
if applicable, and oxygen support 
procedures. 
Record SpO2 while participant is at 
rest.
Screening visit only : SpO2 wh ile 
breathing room air. Data not 
collected on CRF.
Day 1 timing (for each 
administration) :
immediately before 
administration
every 15 minutes during the 
infusion, as possible and 
applicable
Approximately 30 minutes after 
the end of the first infusion
every 30 minutes for 1 hour 
after the last administration. 
During each infusion, only record 
pulse rate, BP and SpO2. 
Automation may be used. See 
Section 8.2.2 for data collected on 
CRF.
All other study days: once daily. 
Hospitalization 
eventsDaily X X X X X XRecord if the following events occur 
or occurred since prior visit:
Emergency room visits
Hospitalized
ICU admittance
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
30Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Extended care facility 
admittance, and
Discharge
Clinical status and 
concomitant 
procedures if 
participant is 
hospitalizedDaily  if hospitalized X X X XDocumentation from hospital 
records is acceptable if hospitalized 
at any  time.
Includes the following:
NEWS 2 Consciousness 
(ACVPU)
Limitation on activities due to 
COVID -19 (Patient Global 
Assessment for Daily Activities 
of Phy sical Function)
Concomitant procedures of 
interest for organ support (e.g., 
proning, renal support)
Additional organ support (e.g. ,
pressors, renal replacement). 
Oxygen support and vital signs data 
should be collected while 
participant is hospitalized.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
31Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Laboratory Tests and Sample Collection
Hematology X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Clinical chemistry X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day
No samples needed if participant is 
hospitalized 
Lilly -designated central laboratory
C-reactive protein 
(CRP); high -
sensitivity X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
32Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Ferritin X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
D-dimer X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
Procalcitonin X X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
33Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Troponin I and 
Troponin TX X X X XDay 1: before treatment administration
All other days: sample may occur at any 
time during the day 
No sample needed if participant is 
hospitalized
Lilly -designated central laboratory
Documentation of 
positive SARS -
CoV-2 viral 
infection XSample for first positive test must be 
collected within 3 days prior to start of 
infusion. 
Local laboratory and/or Point -of-Care 
testing.
Urine or serum 
pregnancy X X XOnly for WOCBP (Section 10.4,
Appendix 4) 
Local laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
34Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Pharmacokinetic 
(PK) sample
for
LY3819253
VIR-7831X X X X X XDay 1: VIR -7831 PK will be tested pre -
dose. No LY3819253 pre -dose sample 
needed; one post -dose sample within 30 
minutes after the end of second infusion 
will be shared by LY3819253 and VIR -
7831 (may include the flush). 
All other scheduled samples may occu r 
at any  time during the day.
No samples needed if participant is 
hospitalized.
Lilly -designated central laboratory 
Immunogenicity 
(ADA) sample for
LY3819253
VIR-7831X X X X X XDay 1: collect before treatment 
administration. 
All other scheduled and unscheduled 
immunogenicity samples should be 
collected with a time -matched PK 
sample.
No samples needed if participant is 
hospitalized .
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
35Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Pharmacodynamic 
(PD) NP swab X X X X X X XSwab is taken from both nostrils. 
Day 1: swab before treatment 
administration.
No samples needed if participant is 
hospitalized
Lilly -designated central laboratory
Explo ratory  
biomarker 
samplesX X X X X X Day 1: before treatment administration.
Explo ratory  
serum sampleX X
Pharmacogenetics 
sampleX Lilly -designated central laboratory
Randomization and Dosing
Randomization X
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
36Schedule of Activities for Treatment Arms 7 -8
Study 
J2X-MC-PYAHScreen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment follow -
upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85 169Screening and Day 1 procedures may 
occur on the same day.
* = telephone visit(s) for all treatment 
arms
Visit Window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4 ±7Visits may not be combined.
Administer study 
interventio nXStudy  intervention must be administered 
within 3 days from the time of first 
positive SARS -CoV-2 test sample 
collection.
For participants that receive dialysis on 
the same day as administration of study 
intervention, complete dialysis first 
followed by the study treatment.
Participants will be monitored at least 
30 minutes after the first infusion and at 
least 1 hour after the last infusion.
Participant Questionnaire
Symptoms 
(patient symptom 
assessment) and 
overall clinical 
statusDaily  on Day s 1-11 for outpatients only X X X X X Day 1: assess prior to dosing
Abbreviations: ACVPU = alert, consciousness, verbal, pain, unresponsive scale; ADA = anti -drug antibody; AEs = adverse events; BP = blood pressure; CRF = 
case report form; ED = early discontinuation visit; FiO2 = fraction of inspired oxygen in the air; ICU = intensive care unit; NP = nasopharyngeal; NSAID s= 
non-steroidal anti -inflammatory drugs; SAEs = serious adverse events; SARS -CoV-2 = severe acute respiratory syndrome coronavirus 2; SpO2 = saturation 
of peripheral oxygen; WOCBP = women of child -bearing potential. 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
371.3.3. Treatment Arms 9-14
Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Procedures
Informed Consent X
Informed assent for 
adolescent 
participantsXParent or legal guardian signs informed consent form 
and participant signs assent form, as appropriate per 
local requirements.
Inclusion and 
exclusion criteria 
reviewX
Demographics X Including age, gender, race, ethnicity
Preexisting 
conditio ns and 
medical historyXObtained from interview or available information .
Includes:  vaccination history (inclu ding SARS -CoV-
2 vaccinations) ,risk factors and comorbidities 
associated with severe COVID -19 illness, such as 
living in a nursing home or long -term care facility. 
Prespecified 
medical history: 
COVID -19XIncludes COVID -19 diagnosis date and onset of 
COVID -19 symptoms.
Height X
Weight X
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
38Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Prior treatments of 
special interest 
within the last 30 
daysXNSAIDs, antivirals, antibiotics, anti -malarials, 
corticosteroids, immunomodulators or other 
investigational treatments.
Substance use 
(Tobacco)XIncludes use of e -cigarettes, such as vaping
Concomitant 
medicationsX X X X X X X X X X X X X X X
Adverse events 
(AEs)X X X X X X X X X X X X X X XAny events that occur after signing the informed 
consent are considered AEs as defined in 
Section 10.3.
Additional details regarding reporting frequ ency 
and method of detecting AEs and SAEs can be 
found in Section 8.3.
Physical Evaluation or Clinical Assessments
Physical 
examinationX
Symptom -directed 
physical examX X XAs indicated based on participant status and 
standard of care.  May be performed by 
qualified personnel per local regulations.
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
39Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Vital signs and 
Oxygen SupportX X X X X X X X X X XDocumentation of hospital -based exam is 
acceptable.
Includes: body temperature, pulse rate, BP, 
respiratory  rate, SpO2, and supplemental oxygen 
flow rate, FiO2 if known, method of delivery, if 
applicable, and oxygen support procedures. 
Record SpO2 while participant is at rest.
Screening visit only : SpO2 while breathing 
room air. Data not collected on CRF.
Day 1 timing:
immediately before administration
immediately following completion of 
infusion if infusion is <15 minutes
every 15 minutes during the infusion, as 
possibl e and applic able
every 30 minutes for 1 hour after the end of 
infusion
See Section 8.2.2 for data collected on CRF.
All other study days: once daily. 
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
40Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Hospitalization 
eventsDaily X X X X X XRecord if the following events occur or occurred since 
prior visit:
Emergency room visits
hospitalized
ICU admittance, 
Extended care facility admittance, and
Discharge
Laboratory Tests and Sample Collection
Hematology X X X X XDay 1: before treatment administration
All other days: sample may occur at any time during 
the day
No samples needed if participant is hospitalized
Lilly -designated central laboratory
Clinical Chemistry X X X X XDay 1: before treatment administration
All other days: sample may occur at any time during 
the day
No samples needed if participant is hospitalized 
Lilly -designated central laboratory
C-reactive protein 
(CRP); high -
sensitivity X X X X XFor adults only
Day 1: before treatment administration
All other days: sample may occur at any time during 
the day  
No sample needed if participant is hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
41Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Ferritin X X X X XFor adults only
Day 1: before treatment administration
All other days: sample may occur at any time during 
the day  
No sample needed if participant is hospitalized
Lilly -designated central laboratory
D-dimer X X X X XFor adults only
Day 1: before treatment administration
All other days: sample may occur at any time during 
the day  
No sample needed if participant is hospitalized
Lilly -designated central laboratory
Procalcitonin X X X X XFor adults only
Day 1: before treatment administration
All other days: sample may occur at any time during 
the day  
No sample needed if participant is hospitalized
Lilly -designated central laboratory
Troponin I and 
Troponin TX X X X XFor adults only
Day 1: before treatment administration
All other days: sample may occur at any time during 
the day  
No sample needed if participant is hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
42Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Documentation of 
positive SARS -
CoV-2 viral 
infection XSample for first positive test must be collected within 
3 day s prior to start of infusion.
Local laboratory and/or Point -of-Care testing.
Urine or serum 
pregnancy X X XOnly for WOCBP (Section 10.4 Appendix 4) 
Local laboratory
Pharmacokinetic 
(PK) sample for
LY3853113
LY3819253
LY3832479X X X X X X X XDay 1: no pre -dose sample needed; one post -dose 
sample within 30 minutes after the end of IV infusion
(may include the flush). 
All other scheduled samples may occur at any time 
during the day.
No samples needed if participant is hospitalized.
Lilly -designated central laboratory
Immunogenicity 
(ADA) sample for
LY3853113
LY3819253
LY3832479X X X X X XDay 1:  collect before treatment administration . 
All other scheduled and unscheduled immunogenicity 
samples should be collected with a time -matched PK 
sample.
No samples needed if participant is hospitalized
Lilly -designated central laboratory
Pharmacodynamic 
(PD) NP swab X X X X X X XSwab is taken from both nostrils . 
Day 1: swab before treatment administration.
No samples needed if participant is hospitalized
Lilly -designated central laboratory
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
43Schedule of Activities for Treatment Arm s 9-14
Screen Double -blind treatment and assessments EDFollow -up if 
hospital 
inpatient on 
Day 29Post-treatment 
follow -upComments
Study Day 1 2* 3 4* 5 6* 7 11 22* 29 EDEvery 7 days 
until discharge 
or Day 6060 85Screening and Day 1 procedures may occur on the 
same day.
* = telephone visit(s) for all treatment arms
Visit window 
(number of days)-- -- +1 -- +1 -- +1 -2/+3 ±3 ±3 ±2 ±2 ±4 ±4Visits may not be combined.
Explo ratory  
biomarker samplesX X X X X X Day 1: before treatment administration.
Explo ratory  serum 
sampleX X X
Pharmacogenetics 
sampleXFor adults only
Lilly -designated central laboratory
Randomization and Dosing
Randomization X
Administer study 
interventio nXStudy  intervention must be administered within 3 
days from the time of first positive SARS -CoV-2 test 
sample collection.
For participants that receive dialysis on the same day 
asadministration of study intervention, complete 
dialy sis first followed by the study treatment.
Participants will be monitored for at least 1 hour after 
completion of treatment administration .
Participant Questionnaire
Symptoms (Patient 
Symptom 
Assessment) and 
overall clinical 
statusDaily  on Day s 1-11 for outpatients only X X X X X Day 1: assess prior to dosing
CONFIDENTIAL Protocol  J2X-MC-PYAH(g)
44Abbreviations: ADA = anti -drug antibody; AEs = adverse events; BP = blood pressure; CRF = case report form; ED = early discontinuation visit ; FiO2 = 
fraction of inspired oxygen in the air; ICU = intensive care unit; NP = nasopharyngeal; NSAIDS = non -steroidal anti -inflammatory drugs; PK = 
pharmacokinetics; SAEs = serious adverse events; SARS -CoV-2 = severe acut e respiratory syndrome coronavirus 2; SpO2 = saturation of peripheral oxygen; 
WOCBP = women of child -bearing potential.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
452. Introduction
The efficient community spread of severe acute respiratory  syndrom e coronavirus 2 ( SARS -CoV -
2)has resulted in the current pandemic of coronavi rus di sease 2019 ( COVID -19), which in severe 
and critical cases results in progressive pulmonary infection, complicated by respiratory failure, with 
a high prevalence of acute respiratory distress syndrome. Although sever al therapies have been 
explored in severe COVID -19, none have improved survival, including antivirals, glucocorticoids, 
and immunoglobulins (Liu et al 2020). 
LY3819253 ,LY3832479 , and LY3853113 are neutralizing IgG1 monoclonal ant ibodies (mAb) 
to the spik e protein of SARS -CoV -2. They  are designed to block viral attachment and entry  into 
human cells, and to neutralize the virus, potentially treating even established COVID -19 by  
provi ding a co mbinat ion of specific, potent, neutralizing antibodies to SARS -CoV -2. The 
blocking of viral entry  into respi ratory  cells and viral  replicat ion, and viral neutralizat ion is 
expected to mit igate the severit y of disease in pat ients in who m ongoing viral spread and 
replicat ion is the primary driver of COVID -19 pathophysio logy. The decrease in viral replicat ion 
may also shorten a patient’s extent and duration of viral shedding and transmissio n, posit ively 
impact ing public healt h. 
VIR-7831 isa human IgG1 mAb thatbinds to the spike protein of SARS -CoV -2.It contains 
modificati ons to enhance both respi ratory  mucosal distribut ion and the half -life. An increased 
distribut ion to mucosal tissue is expected to result in higher and more sustained levels o f VIR-
7831 in th e respi ratory  mucosa, whi ch is a potenti al advantage for treatment and prophylaxis.
Study Rationale
This study  aims to eval uate the impact of LY3819253 alone, LY3819253 + LY3832479 , 
LY3853113 alone, LY3853113 + LY3819253 + LY3832479 , and LY3819253 +VIR-7831on 
viral clearance and clinical outcomes in part icipants wi th mild to m oderate COVID -19 illness. 
Addit ionally, this study  aims to characteri ze the safet y profile o f LY3853113 alone and in 
combinat ion with LY3819253 and LY3832479 in participants at high risk of developing severe 
COVID -19 illness .The data from this study  will inform  decisi ons f or the clinical development of 
these neutralizing IgG1 mAbs. 
Background
LY3819253 and LY3832479
Nonclinical informat ion for LY3819253 and LY3832479 isdescribed in each respect ive 
Invest igator’s Brochure (IB).
Lilly is evaluat ing the safet y, tolerabili ty, pharm acokinet ics (PK), and pharmacodynamics (PD) 
of LY3819253 in participants hospitalized for COVID -19, in a rando mized, placebo -controlled, 
doubl e-blind, single ascending dose, Phase 1, first in human study  (Study  J2W -MC-PYAA
[PYAA]) . This study  has com pleted dosing .
Lilly is also evaluat ing the safet y, tolerabili ty, PK, and immunogenicit y of LY3832479 in 
healt hy parti cipants, in a randomized, placebo -controlled, single dose, Phase 1 study  (Study  J2Z-
MC-PGAA [PGAA]) under IND 150707 . Concurrent with Study  PGAA, LY3832479 is also 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
46under development in China in an ongoing Phase 1 clinical study  in healthy parti cipants, Study  
JS016 -001-I.
Lilly is evaluat ing the safet y, tolerabili ty, PK, immunogenicit y and efficacy of LY3819253 
alone, or in combinat ion with LY3832479, in a randomized, placebo -controlled, double -blind
Phase 2 study  in participants with mild to moderate COVID -19 (Study  J2W -MC-PYAB 
[PYAB]). Dose levels administered in Study PYAB were informed by PYAA and PGAA. 
Specific treatment arms in PYAB are evaluat ing the safet y and efficacy of LY3819253 in 
combinat ion with LY3832479 in part icipants wi th risk factors for severe COVID -19. As of 04
November 2020, 542participants received blinded treatment with either placebo or 2800 mg 
LY3819253 + 2800 mg LY3832479 in co mbinat ion. As of that date, there have been no 
discontinuat ions due to AEs. Serious adverse event s were reported for4participants across 
monotherapy  and co mbinat ion arms .
The SAEs were as fo llows: 
asevere SAE of upper abdominal pain in a participant who received placebo
amild SAE of urinary tract infect ion in a participant who received LY3819253 and 
LY3832479 combinat ion therapy
acute my ocardial  infarct ion in a participant who received blinded study  treatm ent wi th
either placebo or LY3819253 2800 mg in co mbination with LY3832479 2800 m g, and
a severe SAE of diabet ic ketoacidosis in a participant who received LY3819253 700 m g 
monotherapy
No infusi on-related reacti ons were reported. One event of facial swelling and 1 event of 
hypersensit ivity was noted on the day  of infusi on, wi th pruri tis as the m ost comm on immediate 
hypersensit ivity event. Other non -immediate hypersensit ivity events reported included rash, 
stom atitis, and urticaria. A total of 20 patients receiving LY3819253 in co mbinat ion with 
LY3832479 developed treatm ent-emergent adverse events (TEAEs). Most TEA ES were mild to 
moderate in severit y, similar across all dose groups, and comparable to placebo. The most 
frequently reported TEAEs were nausea and pruritus.
As of 24 September 2020, one serious infusio n-related reaction was reported in a blinded 
ongoing study  (J2W -NS-I001; ACTIV -2/A5401) of LY3819253 administered at 7000 mg versus 
placebo.
In addit ion, there is an ongo ing Lilly and NIAID collaborative P hase 3 rando mized, double -
blind, pl acebo -controlled trial (Study  J2X-MC-PYAD [PYAD]) evaluating the efficacy and 
safet y of LY3819253 in preventing SARS -CoV -2 infect ion and C OVID -19 in skilled nursing 
and assisted living facilit y residents and staff.
LY3853113
LY3853113 is a novel, highly potent IgG1 neutralizing mAb targeting the spike protein o f 
SARS -CoV -2that was created in partnership with AbCellera Biologics Inc. (AbCell era; 
Vancouver, Canada) .  It binds an epitope within the receptor binding domain (RBD) that is 
distinct fro m those bound by  LY3819253 and LY3832479 .  LY3853113 can neutralize the 
Wuhanreference strain as well as individual residues present in recent varia nts ofconcern (i.e.
L452R, D614G, N501Y, N439K, K417N, and E484K ).  Cri tically, pseudovirus assays 
demonstrate that LY 3853113 can neutralize variants with the specific combinat ion of RBD 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
47residues of the B.1.1.351 (South African origin),B.1.1.28 (P.1/Braz il origin ), B.1.427/B.1.429 
(California origin ), and B.1.526 (New York origin )strains.  These variants were recent ly 
reported in the U nited States (CDC 2021) , thusitisimperat ive that new treatments for these 
emerging variants are developed and depl oyedquickly.
Refer to the LY3853113 IBfor addi tional information.
VIR-7831
In vitro data show VIR -7831 as a highly potent human IgG neutralizing SARS -CoV -2 antibody ,
which has the potential to be an effect ive therapeutic in mild to crit ically ill pat ients with 
COVID -19. Addit ional nonclinical informat ion for VIR-7831 isdescribed in theIB.
Vir Biotechnol ogy is currently conduct ing a first -in-human Phase 2/3clinical study  (COMET -
ICE, [STUDY_ID_REMOVED] ) for the treatm ent of adult patients aged 18 years and older with mild -to-
moderate COVID -19 who are at risk for progression to hospitalizat ion or death. This study  is a 
rando mized, double -blind, mult i-center, pl acebo -controlled trial o f VIR-7831 (500 mg I V)with 2
planned interim analy ses to allow early stopping for fut ility, efficacy or safet y. The study  
includes a lead-in phase to evaluate the safet y and tol erabilit y of VIR -7831 ,followed by  an 
expansio n phase. Fo llowing review of available safet y and to lerabilit y data through Day 15 fro m 
21 participants in the lead-in phase, the independent data monitoring co mmittee triggered 
expansio n of the study  to enroll  addi tional parti cipants across both treatment groups 
(approximately 1340 parti cipants). VIR-7831 is also being studied for treatment of hospitalized 
participants wi th COVID -19 (ACTIV -3-TICO). As of 21 January 2021, two serious infusio n-
related reacti ons(anaphylaxis and bronchospasm) have been reported in a blinded ongoing
hospi talized pati entstudy  (study  number GSK 215149 ;ACTIV 3 TICO) of VIR -7831 
administered at 500 mg v ersus placebo. Both reactio ns required treatment, one required 
epinephrine. Both events resolved.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
48
Benefit/Risk Assessment
LY3819253 ,LY3832479 , and LY3853113
Inform ation on the safet y and tol erabilit y of LY 3819253 in humans will com e from Stud ies
PYAA and PYAB. Information on the safet y and tol erabili ty of LY3832479 will co me from 
StudiesPGAA and PYAB. Inform ation on the safety  and tolerabili ty of LY3853113 will co me 
from Study  PYA H and PYAH Addendum (4).
Anticipated risk is considered low and is based on the known mechanism o f action for hum an 
derived neutralizing ant ibodies in acute viral disease states. LY3819253 ,LY3832479 , and 
LY3853113 consist of highly specific mAbs directed at foreign (non -human) epitope(s). The 
complementari ty determining regions (CDRs) of the mAbs were derived fro m B lymphocy tes of  
2 individually convalescent naturally  SARS -CoV -2-infected patient sand, thus, have und ergone 
natural  posi tive and negat ive selection pressures in vivo , unlike humanized ant ibodies generated 
in mice. No clinically relevant off -target binding has been observed in t issue cross reactivit y 
studi es of  membrane targets in human tissues. Therefore, off -target binding and tissue cross -
reactivit y are considered unlikely .
A theoretical risk is that these intervent ions may cause antibody -dependent enhancement (ADE) 
of viral  replicat ion. This is based on response s observed to some mo noclonal antibody  therapies 
used in other unrelated viral diseases. To address this risk, LY3819253 and LY3832479 have 
been assessed wit h in vitro cell culture models and, for LY3819253, an in vivo nonhuman 
primate model.
The ri sk of clinical ADE i s considered low due to
the structural features of LY3832479, which is engineered to suppress its binding to Fc 
receptors and C1qm
the absence of ADE fro m in vitro studies, and
the absence of ADE fro m in vivo nonhuman primate studies for LY3819253 . 
To date, there is no evidence of productive enhancement of ADE with SARS -CoV -2. 
Addit ional manageable risks associated with most therapeutic monoclo nal ant ibodies are the 
potenti al for infusi on-related hy persensi tivity and cy tokine release react ions. Infusio n-related 
hypersensit ivity react ions have been observed in clinical studies and under the EUA . 
The infusio ns in this study  will be administered at a controlled rate, the study  parti cipants will be 
monitored cl osely , and adj ustm ents in the infusion rate will be made and/or the infusio n stopped, 
if indicated. Addit ional informat ion regarding infusion react ion management opti ons is in 
Secti on6.1.1 .
Clinical worsening of COVID -19 after administratio n of LY3819253 has been reporte dfrom 
post-authorizat ion treatment within 24 hours of infusion. Signs and symptoms may include fever, 
hypoxia or increased respiratory  difficul ty, arry thmia (e.g., atri al fibrillat ion, sinus tachycardia, 
and bradycardia), fat igue, and altered mental status. Som e of these events requi red 
hospi talizat ion. It is not known if these events were related to LY3819253 use or were due to 
progression of COVID -19.Refer to the IB, and EUA Fact Sheet for additional informat ion.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
49Given the data on LY3819253 ,LY3832 479, and LY3853113, the well described safet y profile o f 
other therapeutic mAbs, and the lack of disease directed therapeutic options for patients with 
COVID -19 illness, the overall benefit -risk assessment for this study  is considered favorable. 
VIR-7831
VIR-7831 is a highly  specific human mAb directed at a non -human epitope.  No clinically 
relevant off -target binding has been observed in t issue cross reactivit y studi es of  membrane 
targets in human tissues, thus off -target binding and tissue cross -reactivi ty are considered 
unlikely .  Ant icipated ri sk of VIR -7831 i s considered l ow and i s based on the known mechanism 
of action for human derived neutralizing ant ibodies in acute viral disease states.
Potenti al risksof clinical  significance include infusi on react ions,hypersensit ivity react ionsand 
immunogenicit y.
Theoretical risk sassoci ated wi th mAb administration during vir al infecti on are
The absence o f ADE in a series of in vitro studies
The absence o f effect on cytokine producti on based on in vitro studies
the absence of ADE fro m an in vivo study  with VIR -7831 wild t ype (a non -LS versi on of  
VIR7831) in the Sy rian hamster m odel 
There i s prior clinical  experi ence wi th VIR -7831 in the setting o f early  treatm ent of  COVID -19 
(VIR -7831 -5001). No specific safet y concerns were ident ified in individuals act ively infected 
with SARS -CoV -2. In addit ion, preclinical animal studies administer ing VIR -7831 in the 
prophylact ic setting have also demonstrated reductio n of viral load and less weight loss in VIR -
7831 -treated animals.
Given there are currently limited available preventative measures for COVID -19, the potentially 
higher exposure and/or disease risk of so me part icipants in this study , and strength of the 
preclinical and clinical data, the Sponsor believes the potential benefit of participat ion in this 
study  outwei gh the risks. The overall benefit -risk assessment takes into accoun t the po tential  
benefit of VIR -7831 treatment through the poten tial abilit y to suppress viral replicat ion and clear 
infected cells.
Investigator ’s Brochures
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse e vents of LY3819253 ,LY3832479 ,LY3853113, and VIR -7831 may be found 
in each respect ive IB.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
503. Objectives and Endpoints
Treatment Arms 1 -6
Primary
Characterize the effect of LY3819253 alone and in 
combinatio n with LY3832479 ,compared to placebo on 
SARS -CoV -2 viral loadProportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7 (+2 days)
Secondary
The secondary objectives are to characterize the effect 
of LY3819253 alone and in combination with 
LY3832479, compared to placebo on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 29
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
oDay 7 (±2 day s)
oDay 11 (±2 day s)
Proportio n of participants with viral load greater 
than 5.27 on Day 7 (+2 days) among participants 
enrolled with ≤8 days of s ymptoms prior to 
randomization 
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11 , and 29 )
Time to SARS -CoV-2 clearance 
SARS -CoV -2 viral load AUC assessed through 
Day 11
symptom resolution Time to symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
3, 5, 7, 11 , 22, and 29
Change in symptom score (total of ratings) from 
baseline up to Day s7, 11, 22, and 29 . 
AUC from baseline to Day 11
symptom improveme nt Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 3, 5, 7, 11 , 22, and 29
safety Safety assessments such as AEs and SAEs
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22,60,and 85
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
51oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 29: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care)
oCOVID -19 related emergency room visit, or
odeath 
characterize the pharmacokinetics of LY3819253
and LY3832479Mean concentration of LY3819253 an d 
LY3832479 on Day 29
Exploratory
Characterize emergence of viral resistance to 
LY3819253 and LY3819253 in combination with 
LY3832479Comparison from baseline to the last evaluable 
time point up to Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2. 
Treatment Arms 7 -8
Primary
Characterize the effect of LY3819253 in combination 
with VIR -7831, compared to placebo on SARS -CoV-2 
viral loadProportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7 (+2 days)
Secondary
The secondary objectives are to characterize the effect 
of LY3819253 in combination with VIR -7831, 
compared to placebo on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 29
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance Change f rom baseline to 
oDay 3 (+1 day )
oDay 5 (±2 day s)
oDay 7 (±2 days)
oDay 11 (±2 day s)
Proportio n of participants with viral load greater 
than 5.27 on Day 7 (+2 days) among participants 
enrolled with ≤8 days of symptoms prior to 
randomization 
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11, and 29)
Time to SARS -CoV-2 clearance 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
52SARS -CoV -2 viral load AUC assessed through 
Day 11
symptom resolution Time to symptom resolution 
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
3, 5, 7, 11, 22, a nd 29
Change in symptom score (total of ratings) from 
baseline up to Days 7, 11, 22, and 29.
AUC from baseline to Day 11
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 3, 5, 7, 11, 22, and 29
safety Safety assessments such as AEs and SAEs
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Days 22, 60 ,and 85
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 29: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care)
oCOVID -19 related emergency room visit, or
odeath 
characterize the pharmacokinetics of LY3819253
and VIR-7831Mean concentration of LY3819253 and VIR-7831
on Day  29
Exploratory
characterize emergence of viral resistance to 
LY3819253 in combination with VIR-7831Comparison from baseline to the last evaluable 
time point up to Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
53
Treatment Arms 9-11
Primary
Characterize the effect of LY3853113 alone andin 
combinatio n with LY3819253 andLY3832479 after 
intravenous infusion compared to placebo on SARS -
CoV-2 viral loadProportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7
Secondary
The secondary objectives are to c haracterize the effect 
of LY3853113 alone and in combination with 
LY3819253 and LY3832479 after intravenous infusion 
compared to placebo on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 2 9
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance 75thPercentile of SARS -CoV -2 viral load at Day 7
Change f rom baseline to 
oDay 3
oDay 5
oDay 7
oDay 11
Proportion of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11 , and 29)
Time to SARS -CoV-2 clearance 
SARS -CoV -2 viral load area under the response -
time curve (AUC) assessed through Day 11
symptom resolution Time to symptom resolution 
Time to sustained symptom resolution
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
2-11, 22, and 29
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2-11, 22, and 29
safety Safety assessments such as AEs and SAEs
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 22
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
54Characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 2 9: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care),
oCOVID -19 related emergency room visit, or
odeath 
Characterize the pharmacokinetics of LY3853113 , 
LY3819253, and LY3832479Mean concentration of LY3853113 , LY3819253, 
and LY3832479 on Day 29
Exploratory
Characterize emergence of viral resistance to
LY3853113Comparison from baseline to the last evaluable
time point up to Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2 .
Treatment Arms 12-14
Primary
Characterize the safety profile of LY3853113 alone 
andin combination with LY3819253 and L Y3832479
after intravenous infusion on SARS -CoV-2 viral loadSafety assessments such as AEs and SAEs
Secondary
The secondary objectives are to c haracterize the effect 
of LY3853113 alone and in combination with 
LY3819253 and LY3832479 after intravenous infusion 
on…
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Da y 29
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
SARS -CoV -2 viral load and viral clearance 75thPercentile of SARS -CoV -2 viral load at Day 7
Change f rom baseline to 
oDay 3
oDay 5
oDay 7
oDay 11
Proportio n of participants that achieve SARS -
CoV-2 clearance (Days 3, 5, 7, 11 , and 29)
Time to SARS -CoV-2 clearance 
SARS -CoV -2 viral load area under the response -
time curve (AUC) assessed through Day 11
Proportio n of participants with SARS -CoV-2 viral 
load greater than 5.27 on Day 7
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
55symptom resolution Time to symptom resolution 
Time to sustained symptom resolution
Proportio n of participants demonstrating symptom 
resolution via the symptom questionnaire on Days 
2-11, 22, and 29
symptom improvement Time to symptom improvement
Proportio n of participants demonstrating symptom 
improvement via the symptom questionnaire on 
Days 2-11, 22, and 29
overall participant clinical statusProportio n (percentage) of participants who 
experience these events by Day 22
oCOVID -19 related hospitalization 
(defined as ≥24 hours of acute care)
oDeath
Characterize clinical status for participants Proportio n (percentage) of participants who 
experience these events through Day 2 9: 
oCOVID -19 related hospitalization (defined as 
≥24 hours of acute care),
oCOVID -19 related emergency room visit, or
odeath 
Characterize the pharmacokinetics of LY3853113 , 
LY3819253, and LY3832479Mean concentration of LY3853113 , LY3819253, 
and LY3832479 on Day 29
Exploratory
Characterize emergence of viral resistance to
LY3853113Comparison from baseline to the last evaluable
time point up to Day 29
Abbreviations: AE = adverse event; SAE = serious adverse event; SARS -CoV-2 = severe acute respiratory 
syndrome coronavirus 2 .
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
564. Study Design
Overall Design
This is a Phase 2, randomized ,single -dose study  in parti cipants wi th mild to m oderate COVID -
19 illness. Treatm ent arm s 1-11 are double -blind and placebo controlled, and treatment arms 12 -
14are open label.
4.1.1. Design Outline
Abbreviations: PD = pharmacodynamic; PYAH = Study J2X-MC-PYAH .
Figure 2. Overview of participant flow from time of SARS -CoV -2 symptoms to 
treatment administration . 
Screening
Interested participants will sign the appropriate informed consent and child/ado lescent assent 
docum ent(s) , as appropriate, prior to complet ion of any  procedures. The parti cipant m ay enter 
the study  with a previ ous posi tive SARS -CoV -2 viral  test resul t from an external testing facilit y. 
This test result must be the first time the participant has tested posit ive for SARS -CoV -2.
The invest igator will review symptoms, risk factors and other non -invasive inclusio n and 
exclusio n criteria pri or to any  invasive procedures. If the participant is eligible after this review, 
then th e site will  perf orm the invasive procedures to confirm eligibilit y.
Double -blind Treatment and Assessment Period
This is the general sequence of events during the treatment and assessment period:
Com plete baseline procedures and sample co llection
Parti cipants are randomized to an intervent ion group
Parti cipants receive study  intervent ion, and
Com plete all  safety  monitoring and post -treatment sample collect ion.

CONFIDENTIAL Protocol J2X-MC-PYAH (g)
57This table describes the planned treatment arms.
Treatment 
armsDose Intervention Participant 
Population
1 --- Placebo ---
2 175 mg + 350 mg LY3819253 +LY3832479 ---
3 700 mg + 1400 mg LY3819253 +LY3832479 ---
4 2800 mg + 2800 mg LY3819253 +LY3832479 ---
5 700 mg LY3819253 ---
6 350 mg + 700 mg LY3819253 +LY3832479 ---
7 700 mg + 500 mg LY3819253 +VIR-7831 ---
8 --- Placebo ---
9 175 mg LY3853113 Low risk
10 175 mg + 700mg + 1400 mg LY3853113 + LY3819253 +LY383247 9 Low risk
11 --- Placebo Low risk
12 175 mg LY3853113 High riska
13 175 mg + 700mg + 1400 mg LY3853113 + LY3819253 + LY3832479 High riska
14 175 mg + 700 mg + 1400 mg LY3853113 + LY3819253 + LY3832479 High riskb
aSee Section 5.1, Inclusion Criteria 27 and 28 for definition of high -risk participants applicable for treatment arms 
12 and 13
bSee Section 5.1, Inclusion Criterion 30 for definition of high -risk participants applicable for treatment arm 14
Treatment arm 1 is the corresponding placebo control for treatment arms 2 -4 and 6. 
Treatment arm 8is the correspo nding placebo control for treatment arm 7. 
Treatment arm 11is the corresponding placebo control for treatment arms 9and 1 0.
This table describes the visit and act ivity types for thi s study .
Study Day Activity Visit Type
1 Follow SoA Site 
2, 4, 6, and 22 Follow SoA Telepho ne visit 
3, 5, 7, 11, 29, ED, 60, and 85 Follow SoA May be conducted as outpatient clinic 
or home visit. Symptom assessments 
can be collected via telephone visit.
8, 9, 10 Collection of symptom assessments Telepho ne visit
Early  discontinuation and follow -up Follow SoA May be conducted as outpatient clinic 
or home visit
169(Arms 7 and 8 only) AE/SAE collection , concomitant 
medicationsTelepho ne visit
Abbreviations: SoA = schedule of activities
If a participant is hospital ized, procedures and assessments will cont inue per the SoA
(Secti on1.3). 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
58This table describes discharge fro m hospi tal scenari os if an outpati ent is subsequent ly 
hospi talized.
If hospital discharge… Then…
Occurs prior to Day 29 participants will be asked to complete the remaining 
study assessments at the timepoints indicated in the 
SoA (Section 1.3).
NOTE: Strategies to manage infection risks and reduce 
the burden of return visits should be used by sites, such 
as home visits.
Occurs on the same day as a study assessment visit assessments do not need to be repeated if the study 
assessments occurred within 8 hours of discharge and 
there has been no change in clinical s tatus and the 
information is available to the site.
Does not occur at or prior to Day 29 assessments will continue to occur weekly up to Day 
60 or until hospital discharge, whichever is sooner.
Post-treatment follow -up
Post-treatm ent follow-up assessments will be conducted at Day  60 and Day  85 to assess clinical 
status and for adverse events. Strategies to manage infect ion risks and reduce the burden o f 
return visits may be used by sites, such as ho me visits. For Arms 7 and 8, an addit ional tele phone 
visit will occur on Day  169 to assess for occurrence of any safet y concerns.
Scientific Rationale for Study Design
Overall Design
This study  is designed to evaluate the efficacy of LY3819253 alone,LY3853113 alone,
LY3819253 in combination wit hLY383 2479 in a dose-ranging design ,LY3853113 in 
combinat ion with LY3819253 and LY3832479 , and LY3819253 in co mbinat ion with VIR -7831 
at a single dose in order to inform the clinical drug development plan for these interventions .
Alternat ivedoses , routes of administration (IV or SQ) ,and/or treatm ent combinat ions may also 
be assessed via the addi tion of  treatm ent arms. Up to 100 addit ional part icipants may be 
introduced ei ther for each opti onal treatm ent arm  or in addit ion to an exist ing treatment arm 
(includ ing placebo) .
The fo llow-up at Day  85 adequately covers the duration for immune response for Arms 1 -6and 
Arms 9 -14.Likewise, t he follow-up at Day  169 adequately covers the duration for immune 
response for Arms 7 and 8.
Participant Characteristics
The participant population are those infected with SARS -CoV -2 that have developed symptoms 
consistent with COVID -19. There i s histori cal evidence that pati ents infected with upper 
respi ratory  viruses who are treated early  in thei r disease course have better re sponses to anti -viral 
therapi es (Aoki  etal. 2003). This hypothesis will be tested with a focused subgroup analysis on 
participants who received intervent ion within 8 days o f symptom onset and using a virology 
endpo int (see Section 3).
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
59Low Risk Participants
The popul ation of participants with mild to moderate COVID -19 illness was chosen to evaluate 
if effect ive antiviral antibody therapy may prevent progression to the severe form of COVID -19 
illness by treati ng this popul ation early in their disease course an d prior to respi ratory  
compromise and failure. 
High Risk Participants
The popul ation of participants in treatment arms 12-14are required to have at least 1 risk factor 
for developing severe COVID -19 illness (see Section 5.1, Inclusio n Cri teria 27 and 28 for 
treatm ent arms 12 and 13, and Inclusio n Cri terion 30 for treatm ent arm 14) .  The ri sk factors 
were based on the Centers for Disease Control guidance (CDC 2021 ).  Participants wi th these 
risk factors are at higher risk for more severe disease and hospitalizat ion.
Adolescent Participants
There are no approved treatments for adoles cents infected with SARS -CoV -2 or to prevent 
infect ion in adolescent s with co morbidities that pl ace them  at increased ri sk shoul d they  become 
exposed to SARS -CoV -2.  Adolescents with mild or moderate COVID -19at higher risk for 
severe disease and hospitali zation are included in this study .
To minimize invasive procedures and blood volume collect ion concerns in ado lescents, c ertain 
laboratory  tests and sample collect ionsare excluded for this populat ion.
Interim Reviews
The interim safety  and efficacy  reviews will  inform the clinical drug development plan sfor 
LY3819253 alone,LY3853113 alo ne,LY3819253 in co mbinat ion with LY3832479 ,
LY3853113 in co mbination wit h LY3819253 and LY3832479 , and LY3819253 in co mbinat ion 
with VIR-7831 . 
Justification for Dos e
LY3819253
LY3819253 700 mg wasestimated as the maximum therapeut ic dose based on PK/PD viral 
dynamics modeling and has a sustained concentratio n above the in vitro IC90 of viral cell -entry  
neutralizat ion in the lung tissue for at least 28 days in 90% of the participant populat ion.The 
maximum dose of 2800 m gwas selected to enco mpass the maximum therapeut ic dose range and 
was selected to explore a wide exposure -response range to mit igate uncertainty  and variabilit y in 
the PK and PD and to establish safet y and tol erabili ty ofLY3819253. The l owest LY3819253 
dose of 175 mg was selected to be approximat ely50% of  maximum response (Emax) to increase
the probabilit yof demonstrating a dose or exposure -response relationship .
LY3832479
LY38324 791400 mg dose was selected as the maximum therapeut ic dose based on PK/PD viral 
dynamics modeling and has a sustained concentratio n above the in vitro IC90 of viral cell -entry  
neutralizat ion in the lung tissue for at least 28 days in 90% of the participant populat ion.The 
maximum 2800 mg dose of LY 3832479 wasselected to optimize the evaluation of dose -
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
60response. The lowest dose of 350mg was selected to achieve at least 50% of the maximum 
response to increase the probabilit y of dem onstrating a dose or exposure -response relat ionship . 
VIR-7831
The500 m g dose of VIR -7831is current ly being evaluated in two clinical trials ( [STUDY_ID_REMOVED] 
and [STUDY_ID_REMOVED]), with approximately 250 partici pants dosed to date.
This dose was selected based on extensive nonclinica l data and expected human PK extrapolated 
from cyno molgus monkeys.
LY3853113 alone or in combination with LY3819253 and LY3832479
The intravenous target therapeuti c doses of LY3853113 (175 m g), LY3819253 (700mg)and
LY3832479 (1400 mg)were selected individually using PK /PD m odeling . The PK /PD m odeling 
approach includes in vitro potency  data (i .e. IC90), predi cted human PK, and the expected 
response in terms of maximal reduct ion in viral load. For each drug separately , the intent ion was
to identify a dose t hat result sin drug concentration above IC90 in at least 90% of patients for at 
least 28 day s, and that also resul tsin maximum viral load reduction based on a PK -viral dynamic 
model.Also, 700 mg of LY3819253 and 1400 m g of LY3832479 are the currently  authori zed
doses.
LY3819253 + LY3832479 Combination , LY3853113 + LY3819253 + LY3832479 
Combination, and LY3819253 + VIR -7831 Combination
Arms 2 -4,6-7, 9-10, 12 -14: To provide coverage of the different epitopes on SARS -CoV -2 
receptor bi nding domain sites, the dose select ion rati onale for each single mAb intervent ion in 
the combination is the same as for the individual dose rationale for a single mAb intervent ion. 
Optional Arm(s): The dose levels for optional arms and any additional arms will be determined 
based on interim analysis results in the study  and/orother emerging data. 
End of Study Definition
A parti cipant i s considered to have co mpleted the study  if they have com pleted all  requi red 
phases of the study  includin g the last scheduled procedure shown in the SoA (Section 1.3).
The end o f the study  is defined as the date of last scheduled procedure shown in the SoA 
(Secti on 1.3)for the last participant in the trial glo bally. 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
615. Study Population 
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
Due to the crit icality of participant health, verbal interview of the potential participant, or their 
legal representative or family member, may be the source for disease characterist ics and medical 
history , unless otherwise specified within the eligibilit y criteria.
Inclusion Crit eria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1.For l ow-risk participant arms only: Are ≥18and <65 years of age at the time o f 
rando mizat ionand do not have the risk factors defined in Criterio n 27
27.For high-risk part icipant arms 12 and 13 only:
a.Are ≥18 years of age and satisfy  at least one of the fo llowing risk factors at the 
time of screening
i.Are ≥65 years of age
ii.Have a BMI ≥35
iii.Have chronic kidney disease
iv.Have t ype 1 or type 2 diabetes 
v.Have im munosuppressive disease
vi.Are current ly receiving immunosuppressive treatment, or
vii. Are ≥ 55 y ears of age AND have
1.cardi ovascular di sease, OR
2.hypertensio n, OR 
3.chronic obstructive pulmo nary disease or other chroni c respi ratory  
disease
28.For hi gh-risk part icipant arms 12 and 13 only:
a.Are 12 -17 years of age (inclusive) AND sat isfy at least one of the fo llowing risk 
factors at the time of screening
i.Have a BMI ≥85thpercentile for their age and gender based on CDC 
growth charts (CDC 2017 )
ii.Have sickle cell disease 
iii.Have congenital or acquired heart disease 
iv.Have neurodevelopmental disorders, for example, cerebral palsy 
v.Have a medical -related techno logical dependence, for example, 
tracheostomy, gastrostomy, or posit ive pressure vent ilation (not rel ated to 
COVID -19)
vi.Have asthma or reactive airway or other chronic respiratory  disease that 
requi res daily medicat ion for con trol
vii. Have t ype 1 or type 2 diabetes
viii. Have chronic kidney disease
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
62ix.Have immunosuppressive disease, or
x.Are current ly receiving im munosuppressive treatment.
30.For hi gh-risk part icipant arm 14 only:
a.Are ≥12 years of age and satisfy  at least one of the fo llowing ri sk factors at the 
time of screening
i.Are ≥65 years of age
ii.Are a dults(≥18 y ears of age) with BMI >25 kg/m2, or if age 12 -17, h ave 
BMI ≥85th percent ile for thei r age and gender based on CDC growth 
charts (CDC 2017)
iii.Have c hronic kidney disease
iv.Have t ype 1 or ty pe 2 diabetes
v.Have i mmunosuppressive disease
vi.Are current ly receiving immunosuppressive treatment
vii. Have c ardiovascular di sease (incl uding congenital heart disease) or 
hypertensio n
viii. Have c hronic lung diseases (for example, chronic obstructive pulmo nary 
disease, asthma [m oderate -to-severe], interstit ial lung disease, cy stic 
fibrosis and pulmo nary hypertensi on)
ix.Have s ickle cell disease
x.Have a n eurodevelopmental disorder (for example, cerebral palsy) or other 
condi tions that confer medical co mplexity (for example, genet ic or 
metabo lic syndro mes and severe congenital ano malies) , or
xi.Havea medical -related techno logical dependence (f or example, 
tracheostomy, gastrostomy , or posi tive pressure vent ilation [not rel ated to 
COVID -19])
Disease Characteristics
2.Are current ly not hospi talized
3.Have one or more mild or moderate COVID -19 symptoms ( CDC 2020; FDA 2021 ) 
i.Fever
ii.Cough
iii.Sore throat
iv.Malaise
v.Headache
vi.Muscle pain 
vii. Gastrointestinal symptoms, or
viii. Shortness o f breath with exert ion
ix.Nasal congest ion or runny nose
x.New l oss of smell
xi.Chills
4.Must have sample collection for first posit ive SARS -CoV -2 viral infect ion determin ation 
≤3 days pri or to start of the infusio n
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
63Sex
5.Are m en or non-pregnant women
Reproductive and Contraceptive agreements and requi rements are provided in 
Secti on10.4, Appendix 4. Contraceptive use by men or women should be consistent with 
local regulati ons f or those parti cipat ing in clinical studies. 
Study Procedures
6.Understand and agree to comply wit h planned study  procedures
7.Agree to the collect ion of nasopharyngeal swabs and venous blood
Informed Consent
8.The parti cipant or l egally  authori zed representative give ssigned informed consent and/or 
assent as described in Sect ion 10.1.3 which includes compliance with the requirements 
and restrictions listed in the informed consent form (ICF) and in this protocol 
Exclusion Criteria 
Parti cipants are excl uded fro m the study  if any of the following cri teria apply:
Medical Conditions
9.For l ow-risk participants only: Have a BMI ≥35
Note: BMI i s rounded to the nearest who le number, for example, 34.5 is rounded to 35.
10.Have SpO2 ≤ 93% on room  air at sea l evel or PaO2/FiO2 <300, respiratory  rate ≥30 per 
minute, heart rate ≥125 per minute (FDA resource page, WWW) 
11.Requi re mechanical vent ilation or anticipated impending need for mechanical vent ilation 
12.Have k nown allergies to any  of the com ponents used in the formulat ion of the 
intervent ions
13.Have hemodynamic instabilit y requiring use of pressors within 24 hours of 
rando mizat ion 
14.Suspected or proven serious, active bacterial, fungal, viral, or other infect ion (besides 
COVID -19) that i n the opinio n of the invest igator could const itute a ri sk when taking 
intervent ion
15.Have any co -morbidity requiring surgery  within <7 day s, or that i s considered life -
threatening within 29 days
16.Have any serious conco mitant sy stemic disease, condit ion or disorder that, in the opinio n 
of the invest igator, should preclude participat ion in this study
Other Exclusions
17.Have a history  of a posi tive SARS -CoV -2 serology test
18.Have a history  of a posi tive SARS -CoV -2 test prior to the one servin g as eligibilit y for 
this study
19.Have received an invest igational intervent ion for SARS -CoV -2 prophylaxis wit hin 30 
days before dosing
20.Have received treatment with a SARS -CoV -2 specific mo noclonal ant ibody
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
6421.Have received convalescent COVID -19 pl asma treatm ent 
22.For l ow-risk arms only: Have received a SARS -CoV -2 vaccine OR have participated in a 
previous SARS -CoV -2 vaccine study and are current ly blinded to treatment allot ment
23.Have part icipated, within the last 30 days, in a clinical study invo lving an invest igational 
intervent ion. If the previous invest igational intervent ion has a long half -life, 5 half -lives 
or 30 day s, whichever i s longer, shoul d have passed.
24.Are concurrent ly enrolled in any other type of medical research judged not to be 
scientifically or medically co mpatible wit h this study
25.Are pregnant or breast feeding
26.Are invest igator site personnel directly affiliated wit h this study
29.Have body  weight <40 kg.
Lifestyle Considerations
Reproductive and Contraceptive guidance is provided in Section 10.4, Appendix 4.
Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study but are 
not subsequently enrolled in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Tri als (CONSORT) publishing requirements and to re spond to queries fro m regulatory  
authori ties. Minimal informat ion includes demography, screen failure details, eligibilit y criteria, 
and any  serious adverse event (SAE).
Individuals who do not meet the criteria for participation in this study  (screen failure) may notbe 
rescreened. 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
656. Study Intervention
Study  intervent ion is defined as any invest igational intervent ion(s), m arketed product(s), 
placebo, or m edical  device(s) in tended to be administered to/used by  a study  parti cipant 
according to the study  protocol .
Study Intervention(s) Administered
Each participant will receive a single administration of either placebo , LY3819253, LY3853113,
LY3819253 in co mbination wit hLY3832 479, LY3853113 in co mbinat ion with LY3819253 and 
LY3832479 , or LY3819253 in combinat ion withVIR-7831 .Study interventi on must be 
administered within 3 days of the first positive SARS -CoV -2 test sample collect ion.
Treatment Arms 1 -6
Intervention 
NamePlace bo LY3819253 + 
LY3832479LY3819253 + 
LY3832479LY3819253 + 
LY3832479LY3819253 LY3819253 + 
LY3832479
Dose 
Formulation0.9% sodium 
chloride 
solutionSolution
Dosage Level(s) 
(mg)Not applicable 175 mg + 
350 mg700 mg + 
1400 mg2800 mg + 
2800 mg700 mg 350 mg + 
700 mg
Use Placebo Experimental
IMP and NIMP IMP IMP
Sourcing Commercially 
available 0.9% 
sodium 
chloride 
solutionFrom Lilly
Packaging and 
LabelingCommercially 
available 0.9% 
sodium 
chloride 
solutionStudy Intervention will be provided in glass vials and will be labeled 
appropriately
Abbreviations: IMP = investigational medicinal product.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
66Treatment Arms 7 -8
Intervention Name Placebo LY3819253 + VIR-7831 TBD
Dose Formulation 0.9% sodium 
chloride solutionSolution Solution
Dosage Level(s) 
(mg)Not applicable700 mg + 500 mg TBD
Use placebo Experimental Experimental
IMP and NIMP IMP IMP IMP
Sourcing Commercially 
available 0.9% 
sodium chloride 
solutionFrom Lilly From Lilly
Packaging and 
LabelingCommercially 
available 0.9% 
sodium chloride 
solutionProvided in glass vials and 
labeled appropriatelyProvided in glass vials and 
labeled appropriately
Abbreviations: IMP = investigational medicinal product.
Treatment Arms 9-14
Intervention Name Placebo LY3853113 LY3853113 + LY3819253 + 
LY3832479
Dose Formulation 0.9% sodium 
chloride solutionSolution Solution
Dosage Level(s) 
(mg)Not applicable 175mg 175mg+ 700mg+ 1400mg
Use Placebo Experimental Experimental
IMP and NIMP IMP IMP IMP
Sourcing Commercially 
available 0.9% 
sodium chloride 
solutionFrom Lilly From Lilly
Packaging and 
LabelingCommercially 
available 0.9% 
sodium chloride 
solutionStudy Intervention will be 
provided in glass vials and 
will be labeled 
appropriately.Study Intervention will be 
provided in glass vials and will 
be labeled appropriately.
Abbreviations: IMP = investigational medicinal product.
Infusio n informat ion may be found in the pharmacy  preparati on instructi ons.
Arms 1 -6
Parti cipants shoul d be m onitoredfor at least 1 hour after complet ion of infusio n. The infusio n 
rate m ay be reduced as deemed necessary  if an infusi on react ion is observed (Section 6.1.1.2 ).
Arms 7 -8
Parti cipants shoul d receive LY3819253 or placebo first and should be mo nitored for at least 30 
minutes after complet ion of the LY3819253 or placebo infusionand before infusio n ofVIR-
7831 or placebo . Parti cipants shoul d be m onitored for at l east 1 hour af ter VIR -7831 infusio nor 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
67placebo . The infusio n rate may be reduced as deemed necessary if an infusio n reaction is 
observed (Sect ion 6.1.1.2 ).
This pro tocol  allows some alteration fro m the current ly outlined dosing schedule, but the 
maximum doses will not exceed 2800 m g for LY3819253 or LY3832479 ,and 500 m g for VIR -
7831 .
Arms 9-14
Parti cipants shoul d be m onitored f or at l east 1 hour after complet ion of infusio n. The infusio n 
rate m ay be reduced as deemed necessary  if an infusi on react ion is observed (Section 6.1.1.2 ).
Further details will be included in the pharmacy preparation instructions ( PPI). The site must 
have resuscitat ion equipment, emergency drugs and appropriately training staff available during 
the infusion and for at least 1 hour after the completion of the infusio n. 
6.1.1. Special Treatment Considerations
6.1.1.1. Premedication for Infusions
Prem edicat ion for infusio ns is not pl anned. However, if an infusion react ion occurs during 
administration or if the participant has a medical history  suggesting a potential benefit from 
prem edicat ion, the study  invest igator(s) should determine the appropriate premedicat ion.
The invest igators and sponsor may decide to use premedicat ion if the frequency o f infusion 
reacti ons am ong parti cipants war rants i t.
If minor infusio n reactions are observed, administration of acetaminophen, 500 mg to 1000 mg, 
antihistamines and/or other appropriately indicated medicat ions may be given prior to the start of 
infusio ns for subsequent participants. 
The decisio n to im plement prem edicat ion for infusio ns in subsequent participants will be made 
by the investigator and sponsor and recorded in the study  documentati on. 
Any premedicat ions given will be documented as a concomitant therapy . 
6.1.1.2. Management of Infusion Reactio ns
All participants shoul d be m onitored cl osely, as there is a risk of infusio n reaction and 
hypersensit ivity (incl uding anaphylaxis) wit h any bio logical  agent. 
Symptoms and Signs
Symptom s and si gns that m ay occur as part of an infusio n reaction include, but are not limited to 
fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash 
including urticaria, pruritus, myalgia, hypoxia, rapid heart rate, fatigue, altered mental status, and 
dizziness. 
Infusio n-related react ions severit y will be assessed and reported using the Divisio n of AIDS
(DAIDS) Table for Grading the Severit y of Adult and Pediatri c Adverse Events, version 2.1 
(July 2017). 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
68This table describes the severit y of react ions according to DAIDS. 
Parameter Mild Moderate Severe Severe and 
Potentially 
Life-threatening
Acute Allergic 
ReactionLocalized urticaria 
(wheals) with no 
medical intervention 
indicatedLocalized urticaria 
with intervention 
indicated 
OR 
Mild angioedema 
with no intervention 
indicatedGeneralized Urticaria 
OR
Angioedema with 
interventio n indicated 
OR
Symptoms of mild 
bronchospasmAcute anaphylaxis 
OR 
Life-threatening 
bronchospasm 
OR
Laryngeal edema
Cytokine 
Release 
SyndromeaMild signs and 
symptoms 
AND
Therapy , that is, 
antibody infusion 
interruption not 
indicatedTherapy  (that is, 
antibody infusion) 
interruption 
indicated
AND
Responds promptly 
to sy mptomatic 
treatment
OR
Prophy lactic 
medications 
indicated for ≤24 
hoursProlonged severe 
signs and symptoms 
OR
Recurrence of 
symptoms following 
initial improvementLife-threatening 
consequences 
(for example, 
requiring pressor or 
ventilator support)
aA disorder characterized by nausea, headache, tachycardia, hypotension, rash, and/or shortness of breath.
Source: Division of AIDS (DAID S) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 
2.1 (July 2017).
Site Needs
The clinical site should have necessary equipment and medicat ions for the m anagement of any 
infusio n reaction, which may include but is not limited to oxy gen, IV fluid, epinephrine, 
acetaminophen and ant ihistamine.
Management of Infusion Reactions
Invest igators should determine the severit y of the infusio n reaction and manage infusion 
reacti ons based on standard of care and their clinical judgment. I f an infusio n reaction occurs, 
then supporti ve care should be used in accordance with the signs and symptoms.
If a participant permanent ly discontinues fro m study  intervent ion, they  shoul d com plete AE 
monitoring and other procedures as stated in the SoA (Section 1.3). 
6.1.2. Temporary Stopping Criteria
The Assessment Committee (AC) members individually will review unblinded safet y data and 
meet as described in the AC Charter. The AC will conduct a full safet y review before 
determining if enro llment should be stopped and/or other study  param eters shoul d be modified. 
(see Section 9.6).
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
69This table describes the location of AE -related info rmation in this protocol.
Topic Location
DAIDS table describing severity of reactions Section 6.1.1.2
Definitio n of AEs Section 10.3.1
Assessment of Intensity/Severity Section 10.3.3
Abbreviations: DAIDS = Division of AIDS. 
Changes to the planned dosing schedule must be appropriately documented and communicated 
with the study  personnel and the IRB/IEC before dosing cont inues. 
Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate storage conditions have been maintained 
during transit for all study  intervent ion received and any  discrepancies are reported and resolved 
before use of the study  interventi on.
To protect blinding, the intervent ions m ust be prepared by  an unbli nded si te personnel  qualified 
to prepare study  intervent ion who are not invo lved in any other study -related procedures. 
Instructi ons for preparation will be provided by  the sponsor.
Only participants enro lled in the study may receive study intervent ion and only authori zed si te 
staff may supply or administer study  intervent ion. 
All study  intervent ion must be stored in a secure, environmentally controlled, and monitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions wit h access limited 
to the invest igator and authorized site staff.
The invest igator or designee is responsible for study intervent ion accountabilit y, reconciliat ion, 
and record maintenance (i.e., receipt, reconciliation, and final disposit ion records).
Further gui danc e and informati on for the final  disposi tion of  unused study  interventi ons are 
provi ded in the pharmacy manual .
Measures to Minimize Bias: Randomization and Blinding
Randomization
All parti cipants will be centrally  randomized to study  intervent ion using an Interactive Web 
Response Sy stem  (IWRS). Before the study  is initiated, the l og in informat ion and directions for 
the IWRS will be provided to each site.
Parti cipants will be stratified by  durati on since symptom onset to randomization ( ≤8days versus 
>8 day s).For treatment arms 12-13, parti cipants will also be stratified by whether they  received 
a SARS -CoV -2 vaccine or not prior to screening.
For arm s 1-11, a ll eligible part icipants will be randomized, init ially following an equal  allocation 
to treatment a rms. For arm s 12-13, eligible participants will be rando mized following a 2:1 
allocat ion to treatment arms. Periodicadjust ments to the allocat ion rati o, inform ed by  planned 
interim analyses, may be made in an effort to achieve an equal allocat ion across t he treatment 
arms at the end of enrollment. Given the staggered start of treatment arms, additional parti cipants 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
70may beenrolledin exist ing treatment arms and the allocat ion rati o may change accordingly . See 
Secti on 9.5for details. 
Parti cipants will be assigned to treatment arm 14 after treatm ent arms 12 and 13 have completed 
enrollment.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
71Blinding
Treatment a rms 1-11 will be blinded . Nei ther partici pants, n or invest igators, nor the sponsor 
study  team  will be aware of treatment assignments prior to the final data base locks at the 
concl usion of the study . Treatm ent arm s 12-14 will be open l abel.
This table describes general procedures for unblinding.
Unblindi ng (IWRS) Emergency unblinding for adverse events may be performed through the 
IWRS. All actions resulting in an unblinding event are recorded and 
reported by the IWRS
In case of an emergency, the investigator has the sole responsibility for 
determining if unblinding of a participants’ intervention assignment 
iswarranted
Participant safety must always be the first consideration in making such a 
determination. However, the investigator should make all attempts to 
contact the Medical Monitor in advance of un blinding
If a participant’s intervention assignment is unblinded, the sponsor must be 
notified immediately after breaking the blind even if consultation occurred 
in advance
The date and reason that the blind was broken must be recorded in the 
source docume ntation and case report form. 
Abbreviations: IWRS =interactive web -response sy stem.
If an invest igator, site personnel performing assessments, or participant is unblinded while the 
infusio n is ongoing, the participant must be discontinued fro m the study intervent ion and the 
infusio n stopped. If any amount of study  intervention was administered, follow procedures 
according to the SoA (Secti on 1.3). 
Study Intervention Compliance
Parti cipants will receive study  intervent ion directly fro m the invest igator or designee, under 
medical supervisio n. The date and time of dosing will be record ed in the source documents and 
recorded in the CRF. The dose of study  intervent ion and study  parti cipant i dentificat ion will be 
confirmed at the time of dosing by a member of the study  site staff other than the person 
administering the study  interventi on. 
Concomitant Therapy
Prior Treatment 
Any pri or therapy , such as antivirals, antibiot ics, or anti -malarials used in the prior 30 day s to 
signing informed consent should be recorded.
Any SARS -CoV -2vaccine should be recorded.  Any non-SARS-CoV -2 vaccine received in the 
prior 90 days to signing informed consent should be recorded.
Therapy  prior to enrollment wi th antivi rals including l opinavir/ri tonavir, rem desivir, or other 
therapeuti c agents (e.g. ,corticosteroids) are permit ted. 
Convalescent COVID -19 pl asma treatment i s not allowed prior to enrollment.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
72Concomitant Therapy
Parti cipants shoul d be treated according to standard of care, even as it evo lves, and medicat ions 
may be part of the treatment paradigm. Therefore, remdesivir may be init iated as standar d of care 
for hospi talized participants (if available through the FDA Emergency  Use Authori zations) 
outsi de of  local standard of care per written policies or guidelines. 
If the local standard of care per written policies or guidelines (that is, not just a n individual 
clinician decisio n) includes lopinavir/ritonavir, chloroquine, hydroxychloroquine or other 
investigat ional agents, then init iating these during the study is permitted, but may require 
additional safety  monitoring by  the si te. 
Convalescent COVID -19 pl asma treatm ent is not allowed. 
Any medicat ion, invest igational agent, or vaccine, including over the counter or prescript ion 
medicines, vitamins, and/or herbal supplements, or other specific categories of interest that the 
participant is receiving at the time of enro llment or receives during the study must be recorded 
along wi th
Reason for use
Dates of administration including start and end dates, and
Dosage information including dose and frequency for concomitant therapy of special
interest.
Acetaminophen and corticosteroid use are permitted at any t ime during the study . 
Other concomitant medicat ion may be considered on a case -by-case basis by the invest igator in 
consultation wit h the sponsor if required .
The sponsor should be cont acted if there are any questions regarding conco mitant or pri or 
therapy .
Dose Modification
No dose m odificat ions are pl anned for thi sstudy .
Intervention after the End of the Study
No continued access is planned after complet ion of this study , as addi tional efficacy woul d be 
needed to demonstrate continued access criteria.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
737. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati on of  specific sites or of the trial as a who le are handled as part of regulatory, 
ethical, a nd trial  oversight consi derat ions in Sect ion10.1.9 , Appendix 1.
Discontinuation of Study Intervention
In rare instances, it may be necessary for a participant to permanent ly discont inue (definit ive 
discontinuat ion) study  intervent ion. If the study  treatm entis definit ively discont inued, the 
participant willremain in the study  forthe rem ainder of the assessment visits through Day  29 
and also for the post-treatm ent follow-up visit s on Days 60 and 85 for all treatment arms and 
Day 169 f or treatm ent arms 7 and 8 as described in the SoA (Section 1.3).
Participan t Discontinuation/Withdrawal from the Study
A parti cipant m ay withdraw from  the study  
at any  time at his/her own request 
at the request of his/her designee (for example, parents or legal guardian)
at the di screti on of  the invest igator for safet y, behavi oral, com pliance, or administrative 
reasons
if the participant beco mes pregnant during the study , or
if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study .
If the participant, for any  reason, requi res treatment with another therapeutic agent that has been 
demonstrated to be effect ive for treatment of the study  indicati on, discont inuat ion from the study  
occurs pr ior to introduction of the new agent.
Discontinuati on is expected to be unco mmo n.
At the time of discont inuat ion, if possible, an early discont inuat ion visit should be conducted as 
described in the SoA (Section 1.3). The parti cipant shoul d also return for the post -treatment 
follow-up visits. 
If the participant discont inues on the same day as a normally scheduled visit, only one set of 
laboratory  tests, sample co llection and assessments are collected.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may  retain 
and cont inue to use any data collected before such a withdrawal o f consent. If a participant 
withdraws fro m the study , they  may request destructi on of  any samples taken and not tested, and 
the invest igator must document this in the site study records.
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not m eet enrollment cri teria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  intervent ion unless 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
74there are extenuating circumstances that make it medically necessary for the participant to 
continue study  intervention. 
If the invest igator and the sponsor CRP agree it is medically appropriate to continue, the 
investigator must obtain documented approval from the sponsor CRP to allow the inadvertently 
enrolled participant to continue in the study with or without tr eatment with investigational 
product. 
Safety follow-up is as outlined in 
Secti on 1.3(Schedule of Act ivities) 
Secti on 8.2(Safet y Assessments), and 
Secti on 8.3(Adverse Events and Serious Adverse Events).
Lost to Follow up
A parti cipant will  be considered l ost to follow -up if they repeatedly  fail to return for scheduled 
visits and is unable to be co ntacted by the study  site. Site personnel are expected to make diligent 
attem pts to contact parti cipants who fail to return for a scheduled visit or were otherwise unable 
to be fo llowed up by  the si te.
Site personnel, or an independent third party , will  attempt to collect the vital status of the 
participant wi thin legal  and ethical boundari es for all  parti cipants that received study  
intervent ion. Public sources may be searched for vital status informat ion. If vital status is 
determined to be deceased, this will be docum ented and the participant will not be considered 
lost to fo llow-up. Sponsor personnel will not be invo lved in any attempts to collect vital status 
inform ation.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
758. Study Assessments and Procedures
Study  procedures and thei r timing are summarized in the SoA (Secti on 1.3). 
Protocol waivers or exempt ions are not allowed.
Moni toring of blinded safet y data will cont inue throughout the study and will be conduct ed by  
blinded study  team  members. Details o f the blinded safet y reviews, including the frequency  and 
approximate timing, are specified in the trial level safet y review pl an.
Immediate safet y concerns shoul d be discussed wit h the sponsor immediately upon oc currence or 
awareness to determine if the participant should cont inue or discont inue study intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential part icipants 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participants screened and to confirm eligibilit y or record reasons for screening failure, as 
applicable.
Efficacy Assessments
Hospi talizati on events (Secti on 8.2.4 ), procedures of special interest (Section 8.2.5 ), vital signs 
(Secti on 8.2.2 ) and symptomo logy (Secti on 8.1.1 )will be used to c haracterize the effect of 
LY3819253 alone,LY3853113 alo ne,LY3819253 in co mbinat ion withLY3832479, 
LY8353113 in co mbination wit h LY3819253 and LY38 32479, or LY3819253 in combinat ion 
withVIR-7831 compared to pl acebo on clinical status from baseline to Days 3, 5, 7, 11 , 22 and 
29.
8.1.1. Symptoms and Overall Clinical Status Participant Questionnaire
Parti cipants will rate thei r overall clinical status and severit y of symptom s associ ated wi th 
COVID -19 by  adaily  questi onnai re. This quest ionnaire is for outpatients only.
Parti cipants will com plete three questions about their overall clinical status daily, including 
severi ty of symptom s 
general physical healt h, and 
change in overall healt h.
The quest ionnaire contains these symptoms 
cough 
shortness of breath 
feeling feverish 
fatigue 
body  aches and pain 
sore throat 
chills 
headache
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
76loss of appet ite, and
changes in taste and smell. 
Each symptom will be scored daily by the participant as experienced during the past 24 hours. 
Rating Score
None or absent 0
Mild 1
Moderate 2
Severe 3
Parti cipants will rate changes in taste and smell with a y es/no response.
Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
8.2.1. Physical Examinations
A co mplete physical examinat ion will be performed at the screening visit. This examinat ion 
excludes pelvic, rectal, a nd breast examinat ions unless clinically indicated.
A symptom -directed physical  examinat ion will be performed at other visits, as specified in the 
SoA and as clinically indicated.
Invest igators should pay special attention to clinical signs related to COV ID-19, to ongoing 
medical condit ions and to previous serious illnesses.
8.2.2. Vital Signs
Vital signs will  be measured as specified in the SoA (Secti on 1.3) and as clinically indicated. 
Vital signs include
Body  temperature
Blood pressure
Pulse rate
Respiration rate
Saturati on of  peripheral  oxygen, and
Suppl emental  oxygen fl ow rate, Fi O2 if known , and method of delivery , if applicable.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
77Thesetable soutline Day  1 vital signs data collect ion on the CRF in relat ion to the infusio n(s). 
Infusio n times may vary  depending on the participant. 
Arms 1 -6
Timepoint (minutes) Collect data on CRF
Immediately before infusion Yes
During Infusion, as possible (if applicable) --
   15 No
   30 Yes
   45 No
   60 Yes
After Administration –every 30 minutes for 1 hour after the end of the infusion --
Abbreviations: CRF = case report form. 
Arms 7-8
Timepoint (minutes) Collect data on CRF
Immediately before first infusion Yes
During first i nfusion, as possible (if applicable) --
   15 No
   30 Yes
   45 No
   60 Yes
After first infusion –30 minutes --
After last infusion –every 30 minutes for 1 hour --
Arms 9-11, 13,14
Timepoint (minutes) Collect data on CRF
Immediately before infusion Yes
If infusion is <15 minutes, immediately following completion of infusion Yes
During Infusions > 15 minutes, as possible (if applicable) --
   15 No
   30 Yes
   45 No
   60 Yes
After infusion –every 30 minutes for 1 hour after the end of the infusion --
   end of infusion +30 minutes Yes
   end of infusion +60 minutes No
Addit ional vital signs may be m easured during the study  if warranted, as determined by the 
investigator.
8.2.3. Clinical Laboratory Assessments
See Secti on 10.2,Appendix 2 for the list of clinic al laboratory  tests to be performed and the SoA 
(Secti on 1.3) for the timing and frequency. All protocol -requi red laboratory  assessments, as 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
78defined in Appendix 2, must be conducted in accordance with the laboratory manual and the 
SoA.
Clinically signi ficant abnormal laboratory  findings are those which are not associated with the 
underlying disease, unless judged by the invest igator to be more severe than expected for the 
participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion 
in the study  or wi thin 28 days after the dose of study  intervent ion shoul d be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by the 
investigator or sponsor .
If such values do not return to normal/baseline wit hin a peri od of  time judged reasonable by  the 
investigator, the etiology  shoul d be i dentified and the sponsor notified.
The invest igator must review the laboratory report, document this review, and recor d any  
clinically relevant changes occurring during the study  in the AE section of the CRF. 
The l aboratory  reports m ust be filed wit h the source documents. 
All protocol -requi red laboratory  assessments, as defined in Appendix 2, must be conducted in 
accord ance with the laboratory  manual and the SoA (Secti on 1.3).
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are considered 
clinically significant by  the investi gator (e.g., SAE or AE or dose modificat ion), report in the AE 
section of the CRF.
Pregnancy Testing
Women of childbearing potential (WOCBP) m ust undergo pregnancy  testing according to the 
SoA. Participants who are pregnant will be discontinued from the study .
8.2.4. Hospitalization events
If a participant is admitted to the hospital, the participant will remain in the study and fo llow the 
procedures o utlined in the SoA (Section 1.3). Hospitalizat ion is defined as ≥24 hours of acute 
care.
The date of hospitalization events will be recorded in the CRF and includes
hospitalizati on 
emergency room  visit 
ICU admittance
Extended care facilit y admi ttance, and 
Discharge.
8.2.5. Procedures of Special Interest
The parti cipants’ clinical status and concurrent procedures of special interest will be recorded in 
the CRF and include consciousness status using the alert, consciousness, verbal, pain, 
unresponsive scale (ACVPU), limitat ion on activit ies due to COVID -19 using the patient global 
assessment for daily act ivities o f physical funct ion, and requirements for 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
79ongoing hospital medical care
supplemental  oxygen
non-invasive vent ilation or a high flow oxygen device 
mechanical vent ilation
ECMO, or
additional organ s upport (e.g. ,pressors, renal replacement).
8.2.6. Respiratory Support
Once enro lled in the study, participants may be managed wit h high -flow nasal  cannula, 
noninvasive posit ive pressure vent ilation or any  other form  respi ratory  support as needed per 
investigator discret ion. 
Adverse Events and Serious Adverse Events
AEs will be reported by  the parti cipant, or, when appropriate, by  a caregiver, surrogate, or the 
participant's legally  authori zed representative.
The invest igator and any qualified designees are respo nsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ion or study .
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All AEs and SAEs will be collected from the time of signing of  the informed consent form (ICF)
until participation in study  has ended .
Adverse e vents that begin before the start of study  intervent ion but after signing of the ICF will 
be recorded on the Adverse Event CRF.
Although all AEs after signing the ICF are recorded by the site in the CRF/electronic data entry, 
SAE reporting to sponsor begin s after the participant has signed the ICF and has received study  
intervent ion. However, if an SAE occurs after signing the ICF, but prior to receiving study  
intervent ion, it needs to be reported within the SAE reporting t imeframe if it is considered 
reaso nably possibly related to study procedures.
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Section 10.3,Appendix 3. The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available. 
Invest igators are not obligated to actively seek AEs or SAEs after concl usion of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or stu dy participatio n, the invest igator must prompt ly notify  the 
sponsor .
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
808.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the prefe rred m ethod to i nquire about AE 
occurrences.
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs will be fo llowed until reso lution, stabilizat ion, the event 
is otherwi se explained, or the participant is lost to fo llow-up (as defined in Sect ion 7.3). Further 
inform ation on fo llow-up procedures is provided in Section 10.3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to t he sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both th e local regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion under clinical investigation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Institutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (e.g., summary  or list ing of SAEs) from the sponsor will review and then file 
it with the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
8.3.5. Pregnancy
Details o f all pregnancies in female participants will be co llected .
If a pregnancy  is reported, the investigator should infor m the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Sect ion 10.4, Appendix 4.
Abnorm al pregnancy outcom es, for example, spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, and ectopic pregnancy, are considered SAEs. 
8.3.6. Hypersensitivity React ions
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity 
reacti ons. 
If such a react ion occurs, additional details describing each symptom should be provided to the 
sponsor in the infusio n-related reacti on/hypersensiti vity CRF.  
If symptoms and/or signs occur during or within 6 hours after infusio n and are believed to be 
hypersensit ivity or due to cy tokine release, then investigators are encouraged to report the event 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
81as infusio n-related immediate hypersensit ivity reac tion or cy tokine rel ease-associ ated infusio n 
reacti on, respectively.
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving intervent ion. It i s recommended that participants 
who experience a systemic hypersensit ivity react ion be treated per the local standard of care.  
In the case of generalized urticaria or anaphylaxis, addit ional blood and urine samples should be 
collected as described in Section 10.6, Appendix 6, “ Reco mmended Laboratory  Testing for 
Hypersensi tivity Events”. Laboratory results are provided to the sponsor via the central 
laboratory . 
In case of skin lesio ns or rash consistent with vasculit is, efforts should be made to perform the 
following as soon as possible
derm atology consul tation
skin biopsy, and
photographs of lesio ns of interest, including skin biopsy site.
8.3.7. Infusion -related Reactions
As wi th other mAbs, infusio n-related reactions may  occur during or following IV administration. 
If an infusio n-related reacti on occurs, addi tional data describing each symptom and sign should 
be provided to the sponsor in the CRF.
This table describes the location of  infusi on-related reacti on inform ation in this protocol.
Topic Location
Special treatment considerationsSection 6.1.1
Premedication for infusions Section 6.1.1.1
Management of infusion reactions Sectio n 6.1.1.2
DAIDS table describing severity Section 6.1.1.2
Treatment guidelines for infusion -related reactions Section 6.1.1.2
Symptom s occurring during or after infusio n of study  intervent ion may also be defined according 
to AE categories such as acute allergic reaction or cy tokine release syndrome (refer to DAIDS).  
8.3.8. Product Complaints
A product complaint is any written, electro nic, or oral communicat ion that alleges deficiencies 
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness or performance o f a 
trial intervent ion.
Sponsor collects product complaints on study  intervent ion and drug delivery system s used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
82Parti cipants will be instructed to contact the invest igator as soon as possible if they have a 
complaint or problem wit h the intervent ionso that the si tuation can be assessed.
NOTE: AEs/SAEs that are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 10.3 of the protocol.
Time Period for Detecting Product Complaints
Product complaints that resul t in an adverse event will be detected, documented, and reported to 
the sponsor during all periods of the study  in which the intervent ion is used.
If the invest igator learns of any product complaint at any time after a participant has been 
discharged from  the study , and such incident is considered reasonably related to an intervent ion 
provi ded for the study , the invest igator will pro mptly notify  the sponsor.
Prompt Reporting of Product Complaints to Sponsor
Product complaints will be reported to t he sponsor within 24 hours after the invest igator beco mes 
aware of the complaint.
The Product Complaint Form will be sent to the sponsor by  a method desi gnated by  the sponsor.
Follow -up of Product Complaints
Follow-up applies to all participants, including those who di scont inue study intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product complaint.
New or updated informat ion will be recorded on the originally co mpleted form wit h all changes 
signed and dated by  the invest igator and submitted to the sponsor.
Treatment of Overdose
There i s no known ant idote for an overdose of LY3819253 alone,LY3853113 alone, 
LY3819253 in co mbination withLY3832479, LY3853113 in co mbinat ion with LY3819253 and 
LY3832479 , or LY3819253 in combinat ion withVIR-7831 . 
In the event of an overdose, the invest igator should
1.Contact the sponsor immediately.
2.Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities 
3.Provi de supportive care as necessary , and
4.Docum ent the quanti ty of the excess dose in the CRF.
Decisio ns regarding infusio n interrupti ons or m odificat ions will be made by the inve stigator, in 
consultation wit h the sponsor, based on the clinical evaluat ion of the participant.
Pharmacokinetics
Venous blood samples will  be collected as specified in the SoA (Secti on 1.3)for determinat ion 
of concentrati ons of  LY3819253 ,LY3832479 , LY3853113, and VIR -7831 used to evaluate the 
PK for LY3819253 ,LY3832479 , LY3853113, and VIR -7831 .  
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
83A maximum of 3samples m ay be collected at additional t ime po ints during the study if 
warranted and agreed upon between the invest igator and the sponsor.
Instructi ons for the collect ion and handling of bio logical samples will be provided by Lilly. 
Site personnel will record
The date and time (24 -hour cl ock time) of admi nistrati on (start and end of infusio n), and
The date and time (24 -hour cl ock time) of each PK sample.
It is essent ial that the times are recorded accurately.  
8.5.1. Bioanalytical
Samples will  be analyzed at a l aboratory  approved by  the sponsor and stored at a f acilit y 
designated by  the sponsor. Concentrations of LY3819253 ,LY3832479 , LY3853113, and VIR -
7831 will be assayed using a validated bioanalyt ical method. Analyses of samples co llected from 
placebo -treated participants are not planned.
Sample retenti on is described in Appendix 1, Section 10.1.12 .Remaining samples used for PK 
may be pooled and used for exploratory  metabo lism or bioanalyt ical method experiments as 
deem ed appropri ate.
Pharmacodynamics
The SARS -CoV -2 viral RNA level  and viral  clearance will  be evaluated by  nasopharyngeal 
swabs. See Section 10.2 Clinical Laboratory Tests, and Section 1.3, the SoA for sample 
collect ion informat ion.  
Sample retenti on is described in Appendix 1, Section 10.1.12 .Remaining samples may  be used 
for addi tional expl oratory  studies to better understand LY3819253, LY3832479 ,LY3853113, 
VIR-7831 and t he disease, which may include sequencing and/or culture of the virus for future 
studi es.
Genetics
A who le blood sample will be co llected for pharmacogenet ic analysis where local regulat ions 
allow.  
See Secti on 10.2, Clinical Laboratory Tests, and Section 1.3, the SoA for sample co llection 
inform ation.  
SeeSecti on 10.5 for genetic researc h, custody , and sam pleretenti on informat ion.
Biomarkers
Blood sam ples will be collected from all part icipants for analysis o f immune system -related 
markers. Serum, who le blood for cellular and/or epigenet ic analysis, and whole blood RNA 
samples for explor atory  biomarker research will be collected at the time specified in the SoA 
(Secti on 1.3) where local regulat ions allow.  
Samples will  be stored and analysis may  be performed on bio markers thought to play a role in 
immune system related responses to viral infect ion including, but not limited to , immune 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
84pathways, cellular composit ion, serum analytes, or epigenet ic bio markers, to eval uate thei r 
associ ation with obser ved clinical responses to LY3819253, LY3832479 , LY3853113, VIR-7831
and the disease state .
Samples may  be used for research to develop methods, assays, prognostics and/or companio n 
diagnosti cs rel ated to the intervention target (S protein), the COVID -19 di sease state, pathways 
associ ated wi th disease, and/or the mechanism of action of the study  intervent ion.
Sample retenti on is described in Section 10.1.12 . 
Immunogenicity Assessments
Visits and times
At the visit s and t imes specified in the SoA (Secti on 1.3), venous blood samples will be co llected 
to determine antibody  producti on against LY3819253 , LY3832479 , LY3853113 and/or VIR -
7831 . The actual  date and time (24 -hour cl ock time) of each sample collect ion will be recorded.   
Sample collection, handling, and use
Instructi ons for the collect ion and handling of bl ood sam ples will  be provi ded by the sponsor .
Immunogenici ty may be assessed by a validated assay  designed to detect ADAs in the presence 
of LY3819253 ,LY3832479 , LY3853113 ,and/or VIR -7831 at a laboratory  approved by  the 
sponsor. Antibodies may be further characterized for their abilit y to neutralize the activit y of 
LY3819253 ,LY3832479 , LY3853113 ,and/or VIR -7831 .
Sample retention
Sample retenti on is described in Appendix 1, Section 10.1.12 . 
Health Economics
This sect ion is not applicable for this study.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
859. Statistical Considerations
Statistical Hypotheses
For treatment arms 1 -6, the null hypothesis for the primary endpo int is that there is no difference 
between any of the doses of LY3819253 aloneor in co mbination wit hLY3832479 ,versus
placebo participants inthe proporti onof participants wi th SARS -CoV -2 viral load greater than 
5.27 on Day  7 (+2 days) . 
For treatment arms 7 -8, the null hypothesis for the primary  endpoint is that there is no difference 
between LY3819253 in co mbination wit h VIR -7831 versus placebo participants in the 
proporti on of  parti cipants wi th SARS -CoV -2 viral load greater than 5.27 on Day  7 (+2 day s).
For treatment arms 9-11, the null hypothesis for the primary endpoint is that there is no 
difference betwe en LY38 53113 al one or in combinat ion with LY38 19253 and LY3832479 , 
versus placebo participants in the proporti on of  parti cipants wi th SARS -CoV -2 viral load greater 
than 5.27 on Day 7 .
Sample Size Determination
Sample Size
Treatment arms 1 -6
The init ial planned sample size is approximately 500 participants allocated across five treatm ent 
arms (treatm ent arms 1 -5).The pl anned sample size is approximately 100 participants for 
treatment arm 6. Since treatment arm 6 begins enrollment after treatm ent arm s1-5, addit ional 
participants will be enrolled in treatment arm 1 to ensure at l east a 50% increase in placebo 
participants and concurrent placebo control  for the primary  com parison of treatment arm 6.
Addit ional participants will also be enro lled in treatment arm 3 to ensure at least a 50% increase 
in LY3819253 700mg+LY383 2479 1400 m g parti cipants to provi de concurrent enrollment of 
an additional treatm ent arm .
Up to 100 addi tional participants may  be introduced ei ther for each opti onal treatm ent arm  or in 
addition to an exist ing treatment arm (including placebo). See Section 9.5for interim analysis 
details.
Sample size was determined based on pairwise comparisons of each dose compared to pl acebo. 
An assumed sample size of 100 participants intreatm ent arm s 2, 4 -6 and 150 participants in 
treatm ent arm s 1 and 3 provides greater than 90 % power to test the superiorit y of at least one 
dose ofLY3819253 or the combinat ion of LY3819253 and LY3832479 versus placebo at the 
two-sided 0.05 alpha level ,adjusted for mult iplicit y, onthe proporti on of  partici pants wi th 
SARS -CoV -2 viral load greater than 5.27 at Day  7 (+2 day s). This assumes thetrueunderlying 
proporti on of  participants meeting this endpo int is5% in the LY3819253 arm of 700 mg, and 
LY3819253 + LY3832479 combinat ion treatm ent arm sfor dose levels 2800 mg+2800 mg, and 
700mg+1400 mg, 7% f ordose level 350mg+700mgandfordose level 175mg+350mg,
and 19% in the pl acebo arm . 
Treatment arms 7 -8
The pl anned sam ple size is approximately  100 participants per treatm ent arm .
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
86Sample size was determined based on a pairwise comparisons of LY3819253 in co mbinat ion 
with VIR -7831 compared to pl acebo. An assumed sample size of 100 participants in treatment 
arms 7 and 8 provi des greater than 87% power to test the superiorit y at the two -sided 0.05 al pha 
level, on the proportion of part icipants wi th SARS -CoV -2 viral load greater than 5.27 at Day 7 
(+2 day s). Thi s assumes the true underlying proportion of participants meet ing this endpoint is 
5% in the LY3819253 700 m g + VIR-7831 500 mg treatm ent arm  and 19% in the pl acebo arm .  
The sample size calculat ions were performed using simulat ions from the software EAST©v6.5.  
Periodic adj ustments to the allo cation rati o of partici pants may be made based oninterim 
analyses. See Section 9.5for details.
Treatment arms 9-11
The planned sam ple size is approximately  122participants per treatment arm.
Sample size was determined based on pairwise comparisons of each dose compared to placebo. 
An assumed sample size of 1 22participants per treatm ent arm provi des about 8 4% power to test 
the superi ority of either LY3853 113 al oneor the combinat ion withLY381 9253 and LY3832479 
versus placebo at the two -sided 0.05 alpha level on the proporti on of  partici pants wi th SARS -
CoV -2 viral load greater than 5.27 at Day 7. This assumes the true underlying proportion of 
participants m eeting this endpo int is 12% in both the LY3853 113alonetreatm ent arm and the 
LY3853113 + LY3819253 + LY3832479 combination treatment arm, and 28% in the pl acebo 
arm. 
Treatment arms 12 -14
Approximately  100 parti cipants will be enrolled into treatm ent arm 12 and approximately 50
participants will be enrolled into treatm ent arm 13.  Treatment a rm 12 includes a greater number 
of parti cipants to assess the tolerabilit y of undiluted LY3853113 administration. Approximately 
140 participants will be enro lled into treatm ent arm 14 once treatm ent arms 12 and 13 have 
completed enrollment.
Stratification
Treatment arms 1 -13
Parti cipants will be stratified by  durati on since symptom  onset category  (≤8days versus 
>8days).
Treatment arms 12 -13
Parti cipants will be stratified by  whether a part icipant received a SARS -CoV -2 vaccine or not 
prior to screening.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
87
Populations for Analyses
This table defines the populations for analysis. 
Population Description
Entered All participants who sign the informed consent form
Efficacy All randomized participants who received study intervention and provided at 
least o ne post -baseline measure for the relevant endpoint. Participants will be 
analy zed according to the intervention to which they were randomized. 
(Intentio n to treat) .
Safety All participants randomly assigned and who received study intervention. 
Participants will be analyzed according to the intervention they actually 
received .
Pharmacokinetic All randomized participants who received study intervention and have 
evaluable PK sample. Participants will be analyzed according to the 
intervention they received .
Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofthe Sponsor or its desi gnee.
Unless otherwise specified, treatment effects will be conducted using 2 -sided tests at an al pha 
level of 0.05. No adjust ment for multiplicity will be perform ed in this study . 
Analyses will be performed separately for treatmen t arms 
1-6
7 and 8 ,
9-11,
12 and 13 , and
14.
For treatment arms 12 and 13 , parti cipants who have received a SARS -CoV -2 vaccine prior to 
screening maybe summari zed separately  from those who have not received a SARS -CoV -2 
vaccine pri or to screening ,for all efficacy outcomes .
Details o f the handling of dropouts or missing data will be fully described in the statist ical 
analysis plan (SAP). 
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a prin cipal feature of the protocol. Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the SAP. Addit ional expl oratory  analyses of the data will be conducted as deemed appro priate.
The SAP will be finalized prior to the first final database lock (i.e., first unblinding o f the 
sponsor), and it will include a more technical and detailed descript ion of the statist ical analyses 
described in this sect ion. This sect ion is a summary of the pl anned statist ical analyses of the most 
important endpoints including primary  and secondary  endpoints.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
889.4.1. General Considerations
This table describes the general statist ical methods that m ay be used in this study . 
Method Analysis 
Descriptive Statistics number of participants, mean, standard deviation, 
median, minimum, and maximum for continuous 
measures, and frequency counts and percentages for 
categorical measures
Kaplan -Meier curves and summary statistics Treatment comparisons of time -to-event based 
endpoints
Logistic regression analysis Treatment comparisons of binary variables with 
treatment and randomization stratification variables in 
the model.
Nonparametric 
(for example, Mann -Whitney or van Elteren tests)Treatment comparison of ord inal, nominal and non -
normally  distributed continuous variables.
Addit ional statistical methodol ogy, sensi tivity analyses account ing for missing data, and 
adjustm ents f or covari ates, if any , will  be described in the SAP. 
9.4.2. Primary Endpoints
Treatment Arms 1-11
The primary  endpoint is the proportion of participants with SARS -CoV -2 viral load greater than 
5.27 on Day  7, corresponding to Ct value of 27.5 based on nasopharyngeal swab sampling for 
reverse transcription po lymerase chain react ion (RT -PCR) testing for SARS -CoV -2.  
Statistical hypotheses testing for the primary endpoint will be conducted using a logist ic 
regression model at the two -sided 0.05 l evel.
Full details will be provided in the SAP.
Treatment Arms 12 -14
All invest igational product and protocol  procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of A Es and SAEs for each treatment will be presented by  severi ty and by 
associ ation with intervent ionas perceived by the investigator. Adverse events reported prior to 
rando mizat ionwill be distinguished fro m those reported as new or increased in severit y during 
the study  post -randomizat ion.
Safety param eters that will be assessed include, but are not l imited to, safet y laboratory  
param eters, and vital signs. The parameters will be listed and summarized using standard 
descript ive statistics. Addit ional analysis will be performed if warranted upon review of the data. 
9.4.3. Secondary Endpoints
9.4.3.1. Safety (Arms 1 -11)
Safety analyses will be conducted using the safet y popul ation described above. 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
89All invest igational product and protocol procedure AEs will be listed, and if the frequency o f 
events allows, safet y data will be summarized using descript ive methodol ogy.
The incidence of AEs and SAEs for each treatment will be presented by  severi ty and by 
associ ation with intervent ion as perceived by the investigator. Adverse events reported prior to 
rando mizat ion will be distinguished fro m those reported as new or increas ed in severi ty during 
the study  post -randomizat ion.
Safety param eters that will be assessed include, but are not limited to, safet y laboratory  
param eters, and vital signs. The parameters will be listed and summarized using standard 
descript ive statistics. Addit ional analysis will be performed if warranted upon review of the data. 
9.4.3.2. Additional Secondary Endpoints
Addit ional secondary  endpoints include
Proporti on (percentage) of participants who experience these events by  Day 29
oCOVID -19 rel ated hospi talizat ion (defined as ≥ 24 hours of acute care) , or
odeath.
SARS -CoV -2 viral load change from  baseline to 
oDay 3 
oDay 5
oDay 7
oDay 11
Proporti on of  parti cipants wi th viral load greater th an 5.27 on Day  7among parti cipants 
enrolled with ≤ 8 days of symptoms prior to randomizat ion
Proporti on of  parti cipants that achi eve SARS -CoV -2 clearance (Days 3, 5, 7, 11 , and 29 )
Time to SARS -CoV -2 clearance
SARS -CoV -2 viral load AUC assessed through Day  11.
75thpercentile o f SARS -CoV -2 viral load at Day  7
Time to symptom resol ution 
osymptoms are scored as absent
Proporti on of  parti cipants dem onstrating symptom  resol ution via the symptom quest ionnaire 
on Day s 3, 5, 7, 11, 22, and29
AUC from baseline to Day  11
Change in symptom score (total of ratings) fro m baseline up to Day s 7,11, 22, and 29
Time to symptom improvement
osymptoms scored as moderate or severe at baseline are scored as mild or absent, AND 
osymptoms scored as mild or absent at baseline are scored as absent.
Proporti on of  parti cipants dem onstrating symptom  improve ment via the symptom 
questionnaire on Days 3, 5, 7, 11, 22, and29
Proporti on (percentage) of participants who experience these events by  Day 22
oCOVID -19 rel ated hospi talizat ion (defined as ≥ 24 hours of acute care) 
odeath.
Proporti on (percentage) of parti cipants who experience these events through Day  29: 
oCOVID -19 rel ated hospi talizat ion (defined as ≥24 hours of acute care),
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
90oCOVID -19 rel ated em ergency room  visit, or
odeath .
Characterize the PK of LY3819253 ,LY38324 79, LY3853113 ,and VIR -7831
oMean concentra tion of  LY3819253 and LY 3832479 on Day  29
oMean concentration o f LY3819253 in co mbination with VIR-7831 on Day 29
oMean concentration o f LY3853113 in co mbination with LY3819253 and LY3832479 
on Day  29
Full details o f the analyses will be in the SAP.
9.4.3.3. Pharmacokinetic Analyses 
Pharmacokinet ic analyses will be conducted on data fro m all participants who receive 
intervent ion and have evaluable PK.
Concentration -time data for LY3819253, LY3832479 , LY3853113, and VIR -7831 will be 
summarized descript ively. A popul ation approach using a nonlinear mixed -effects m odeling 
(NONMEM) program may also be performed. 
Study  data m ay be pool ed wi th the resul ts of other studies for populat ion PK and PK/PD analysis 
purposes.
9.4.4. Exploratory Analyses
Full details o f the planne d expl oratory  analyses will be described in the SAP.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate. Study  
resul ts may be pool ed wi th the resul ts of other studies for safet y, PD, or popul ation PK and 
PK/PD analysis purp oses.
9.4.5. Immunogenicity Analyses
If data fro m validated immunogenicit y assays are available, treatment -emergent anti -drug 
antibodies (TE -ADAs) may be assessed. 
Treatment -emergent ADAs are defined as participants
with a 2-fold (1 dilution) increase in t iter than the minimum required dilut ion if no ADAs 
were detected at baseline (treatment -induced ADA) or 
with a 4-fold (2 dilutions) increase in titer compared with baseline if ADAs were detected 
at baseline (treatment -boosted ADA).
The frequency and percentage of parti cipants wi th preexist ing ADA and who are TE -ADA 
positive (TE -ADA+) to LY3819253 ,LY3832479 , LY3853113, and/or VIR -7831 will be 
tabul ated.  
The distribut ion of titers and frequency o f neutralizing ant ibodies (if assessed) for the TE -ADA+ 
participan tsmay also be tabulated.
The rel ationship between the presence of ant ibodies and PK parameters, efficacy response or 
safet y to LY3819253 ,LY3832479 , LY3853113 and/or VIR -7831 may also be assessed. 
Addit ional details may be provided in the SAP. 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
919.4.6. Subgroup A nalyses
This study  is not powered for subgroup analyses; therefore, all subgroup analyses will be treated 
as exploratory .
Subgroup analyses will be conducted for the primary  endpo int. Subgroups may  include 
time of symptom onset to study  rando mizat ion
baseline severit y of COVID -19
age 
sex 
race 
ethnicit y 
baseline weight
baseline body  mass index , or
concomitant medicat ion
Treatment group differences will be evaluated within each category of the subgroup regardless of 
whether the interaction is statist ically significant. If any group within the subgroup is <10% of 
the total populat ion, only  summaries of the efficacy  data wil l be provided, that is, no inferent ial 
testing.
Definit ions for the l evels o f the subgroup variables, the analysis methodology , and any  addi tional 
subgroup analyses will be defined in the SAP. 
Interim Analyses
The ongoing study  may be m odified based on pl anned interim analyses. Based on the observed 
data at the time of the interim analyses, the study may 
suspend enrollment to any treatment arm demonstrating lack of efficacy, and/or
initiate/expand enrollment to an addit ional/exist ing treatm ent arm  (or arm s).
The m odificat ions proposed are done so to ensure participants are being exposed to treatment 
with an acceptable ri sk-benefit profile during the ongo ing trial. Addit ionally, the potential 
modificati ons will provi de informat ion to more fully characterize the dose response profile . 
Moni toring of unblinded safet y data (including AEs, SAEs, and selected laboratory  
measurements) will occur throughout the study  and will be conducted by  Assessment Committee 
(AC) m embers. Details of the unblinded safet y reviews, including the frequency and
approximate timing, are specified in the AC charter. 
An interim analysis is planned when approximately 75 part icipants in each arm (treatm ent arm s 
1-5)reach Day 7. Additional interim analys es may be conducted when at least 50% of
participants in treatme nt arm 6 reach Day 7 and also when at l east 33% of participants in 
treatm ent arm s 7 and 8 reach Day  7.
The approximate timing, decisio n criteria, and statistical methods associated with each possible 
modificati on to the ongoing tri al will be fully  describ ed in the SAP and AC Charter and finalized 
prior to the first study  unblinding.  
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
92Periodic adj ustments to the allo cation rati o may be made to achi eve the planned allocat ion across 
treatm ent arm s at the concl usion of enrollment. If addit ional placebo partic ipants are enrolled, 
then the allocat ion rati o may change accordingly.
Prior to the primary  endpoint, only the AC (and individuals as defined in the unblinding plan) is 
authori zed to eval uate unblinded interim analyses and safet y analyses. Study  sites will receive 
inform ation about interim results only if they need to know for the safet y of their parti cipants. 
Unblinding details are specified in the unblinding plan sect ion of the SAP or in a separate 
unblinding plan document.  
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
93
Data Monitoring Committee (DMC)
The sponsor will form an AC to analyze the interim study data. To minimize any bias introduced 
into the analysis o f the study  resul ts, analysis plans will be finalized and approved prior to the 
interim analyses.
The primary  goal  of the AC is to revi ew the interim results regarding the continuing safet y of 
study  participants and the continuing validit y and sci entific merit of the study. Inform ation that 
may unblind the study  during the analyses will not be reported to study  sites or the blinded study  
team until the study has been unblinded. 
Overall committee structure information is in Sect ion 10.1.5 . Details of the AC will be provided 
in the AC charter.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
9410. Supporting Documentation and Operational Considerations
Appendix 1: Regulator y, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable Internat ional Council for Harmoniza tion (ICH) Good Clinical Practice (GCP) 
Guidelines, and
Applicable laws and regulations.
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by  the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study part icipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other significant safet y findings as required by 
IRB/IEC procedures, and
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH gui delines, the IRB/IEC, European reg ulation 536/2014 for clinical 
studi es (if applicable), and all other applicable local regulat ions.
Invest igator sites are compensated for participat ion in the study  as detailed in the clinical trial 
agreem ent.
10.1.2. Financial Disclosure
Invest igators and sub -investigators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators are 
responsible for providing informat ion on financial interests during the study and for 1 year after 
completion of the study .
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
9510.1.3. Informed Consent Process
The invest igator or their representative will explain the nature of the study, including the risks 
and benefits, to the participant or their legally authorized representative and answer all quest ions 
regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or thei r legally  
authori zed representative will be requi red to si gn a statem ent of  inform ed consent and 
child/ado lescent assent, as appropriate, that meets the requirements of 21 CFR 50, local 
regul ations, ICH guidelines, Health Insurance Portabilit y and Accountabilit y Act (HIPAA) 
requi rements, where applicable , and the IRB/IEC or study  center.
Due to strict respiratory  isolation policies, limited access to COVID -19 patient rooms, and 
SARS -CoV -2 transmissibilit y via droplet -contaminated paper, verbal consent and alternat ive 
methods of obtaining consent (for exam ple, by phone) will be allowed if approved by  the IRB. 
If a signed paper copy  of the ICF or child/ado lescent assent is allowed by site/inst itution policy, 
then the process of how it will be obtained and stored will need to be determined. 
Any variation fr om the standard consent process due to isolat ion and infect ion control should be 
sent to the IRB for approval prior to enrollment. The site will docum ent the process in their 
regul atory  files and demonstrate that the process has IRB concurrence or approval .
The m edical  record m ust include a statem ent that wri tten inform ed consent or child/ado lescent 
assent was obtained before the participant was entered in the study  and the date the written 
consent or assent was obtained. The authorized person obtaining the informed consent or 
child/ado lescent assent, and, if applicable, the individual designated to witness a verbal consent, 
must al so sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during their 
participat ion in the s tudy.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  authori zed 
representative and is kept on file.
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records, datasets 
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant m ust be inform ed that thei r personal  study -related data will  be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent. 
The parti cipant m ust be inform ed that thei r medical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The spon sor has processes in place to ensure data protection, informat ion securit y and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
9610.1.5. Committees Structure
The AC w ill consist of m embers internal and external to the sponsor. The membership will 
include, at a minimum, a chair external to Lilly, a statist ician and two phy sicians. The AC 
members will not have data entry /validat ion responsibilit ies or direct con tact wi ththe site(s) or 
testing facilit ies.  
10.1.6. Dissemination of Clinical Study Data
A clinical study  report will be provided for this study  and a summary  of study  information 
provi ded on publicly  available websi tes. 
10.1.7. Data Quality Assurance
Investigator responsibili ties
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory  data). The invest igator is 
responsible for verifying that data entries are accurate and correct by physically or electronically 
signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC revie w, and regul atory  
agency  inspect ions and provide direct access to source data documents.
Data monitoring and management
The Monitoring Plan includes
monitoring details describing strategy , for example, ri sk-based init iatives in operations 
and qualit y such as Risk Management and Mit igation Strategies and Analyt ical Risk -
Based Monitoring 
methods 
responsibilit ies and requirements 
handling of nonco mpliance issues ,and 
monitoring techniques.
The sponsor or designee is responsible for the data management of t his study  including qualit y 
checking o f the data. The sponsor assumes accountabilit y for acti ons del egated to other 
individuals (e.g., Contract Research Organizat ions).
Study  monitors will perform  ongoing source data verification to confirm that data enter ed into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents. They  will also ensure that the safety  and ri ghts of  parti cipants are being protected, 
and that the study  is being conducted in accordance with the cu rrently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements. 
If on -site monitoring activit ies cannot occur, alternative measures will be used. Examples of 
alternat ive measures are use of techno logy for off -site monitoring or provi ding pseudonymized 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
97copies of  source documents to the monitor electronically. The remote source data verificat ion 
will be focused on crit ical efficacy data and important safet y data. 
Records retention and audits
Records and documen ts, including signed ICFs, pertaining to the conduct of this study  must be 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA) 
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od.
No records may be destroy ed during the retention period without the written approval of the 
sponsor. No records may  be transferred to another locat ion or party  without wri tten notificat ion 
to the sponsor.
The sponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site. The study  may be audi ted by the sponsor or 
its representatives, and by regulatory  agencies at any  time. Investigators will be given notice 
before an au dit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system. 
Only symptom  assessments might be direct ly recorded by the invest igator site personnel or a 
delegate into t he EDC. The direct ly entered data will serve as source documentation. The 
investigator will not maintain an original, separate, written or electronic record of these data. A 
certified copy  of the respect ive data entry will be downloaded by the invest igator for retenti on.
The invest igator is responsible for the ident ificat ion of any  data to be considered source and for 
the confirmat ion that data reported are accurate and complete by  signing the CRF .
Data collected via the sponsor -provided data capture system swill be stored at third parties . The 
investigator will have cont inuous access to the data during the study  and unt il deco mmissio ning 
of the data capture sy stem s.Prior to decommissio ning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention. Data will subsequent ly be transferred fro m the central  vendor to the Sponsor data 
warehouse.
Data from co mplaint forms submitted to Sponsor will be encoded and stored in the global 
product complai nt management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
98Data reported on the CRF that are tra nscribed fro m source documents must be consistent with 
the source documents or the discrepancies must be explained. The investigator may need to 
request previous medical records or transfer records, depending on the study . Current m edical 
records m ust be a vailable.
The definit ion of what constitutes source data can be found in Sect ion10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of 
participants.
Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  siteswill be closed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, pro vided there is reasonable cause 
and enough notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  the investi gator, or
Discontinuati on of  further study  intervent ion developm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
Invest igators, the IECs/IRBs, the regulatory authorit ies, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by th e 
applicable regulatory  requi rements. The Invest igator shall pro mptly inform the part icipants and 
assure appropriate participant therapy  and/or fo llow-up.
10.1.10. Publication Policy
In accordance with the sponsor’s publication po licy, the results of this study  will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
10.1.11. Investigator Information
Physicians with specialt ies, including, but not limit ed to infect ious di sease, acute or crit ical care, 
pulmo nary disease, immunol ogy, or other appropriate specialt ies may participate as 
investigators.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
9910.1.12. Long -Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that m ay not be observed unt il later in the development of  the 
intervent ion or after  the intervent ion beco mes commercially  available.
This table describes the retention period for potential sample t ypes.
Sample Type CustodianRetention Period After Last Participant 
Visit
Pharmacodynamic Samples Sponsor or designee up to 7 years
Pharmacogenetics sample Sponsor or designee up to 7 years
Explo ratory  Biomarker Samples Sponsor or designee up to 7 years
Immunogenicity (ADA) sample Sponsor or designee up to 7 years
Pharmacokinetic (PK) sample Sponsor or designee up to 2 years
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
100
Appendix 2: Clinical Laboratory Tests
Clinical laboratory  tests will  be perf ormed according to the SoA (Secti on 1.3). 
Addit ional tests may be performed at any t ime during the study as determined necessary by the 
investigator or required by local regulat ions.
Central  and l ocal laboratori es will be used. Th e table below describes when the local or central 
laboratory  will be used.
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites or other 
blinded personnel.
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion 5
of the protocol.
Pregnancy testing will be performed according to the SoA.
Invest igators must document their review of each laboratory  safety  report.
Refer to Section 10.6 for recommended laboratory  testing for hypersensit ivity events.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
101Clinical Laboratory Tests Comments  
Hematology Assay ed by Lilly -designated laboratory. 
Hemoglobin
Hematocrit
Erythrocy te count (RBCs -Red Blood Cells)
Mean cell volume 
Mean cell hemoglobin
Leukocytes (WBCs -White Blood Cells) 
Differential
   Neutrophils, segmented
   Lymphocy tes
   Monocytes
   Eosinophils
   Basophils
Platelets
Cell Morphology (RBC and WBC)
Clinical Chemistry Assay ed by Lilly -designated laboratory. 
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK)
Uric acid
Total protein
Albumin
Calcium
Phospho rus
Glucose
Amylase
Lipase
Lactate dehydrogenase (LDH)
SARS -CoV -2 viral infection determination Local laboratory and/or Point -of-Care testing
SARS -CoV -2 Test Panel Assay ed by Lilly -designated laboratory.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
102Clinical Laboratory Tests Comments  
C-reactive protein (CRP); high -sensitivity For adults only
Ferritin For adults only
D-dimer For adults only
Procalcitonin For adults only
Troponin For adults only
Troponin I For adults only
Troponin T For adults only
Hormones (female)
Urine Pregnancy Local laboratory
Serum Pregnancy Local laboratory
Pharmacokinetic Samples  Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   LY3819253
   LY3832479
   LY3853113
   VIR-7831
Pharmacodynamic sample Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   SARS -CoV-2 nasophary ngeal swab
Pharmacogenetics sample For adults only
Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Exploratory Biomarker Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Serum
   RNA (PAXGene)
Whole Blood (EDTA) For adults only
   Whole Blood (EDTA) Epigenetics For adults only
Exploratory Biomarker Serum Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Immunogenicity Samples Assay ed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
   Anti-LY3819253 antibodies 
   Anti-LY3832479 antibodies
   Anti-LY3853113 antibodies
   Anti-VIR-7831 antibodies
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
103
Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical  occurrence in a pati ent or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE Definition
Any abnorm al laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e.g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medi cal and scient ific judgment of the investigator (i.e., not related to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New cond itions detected or diagnosed after study intervent ion administration even 
though i t may have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequel ae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported r egardless of sequelae. 
“Lack of efficacy” or “failure of expected pharmacological act ion” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resu lting fro m lack of efficacy 
will be reported as AE or SAE if they fulfill the definit ion of an AE or SAE. 
Events NOT Meeting the AE Definition
The fo llowing study -specific clinical events related to COVID -19 are exempt fro m 
adverse event reporting unless the invest igator deems the event to be related to the 
administration of study  drug:
oHypoxemia due to COVID -19 requiring supplemental oxygen;
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
104oHypoxemia due to COVID -19 requiring non -invasive vent ilation or high flow 
oxygen devices;
oRespiratory  failure due to COVID -19 requiring invasive mechanical vent ilation 
or ECMO
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or s urgical procedure (e.g., endoscopy , appendectomy): the condit ion that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
Anticipated day -to-day fluctuation s of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e.g., hospitaliza tion for signs/symptoms of the disease under study , death due to 
progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admitted to hospital 
for observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complicat ions that occ ur duri ng hospi talizati on 
are AEs. If a complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, 
the event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE shoul d be considered serious.
Hospit alizati on for elective treatment of a pre -existing condit ion that di d not worsen 
from baseline is not considered an AE.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
105d.Results in persistent disability/incapacity
The term  disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life funct ions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsio ns that do not result in hospi talizat ion, or development of drug dependency or 
drug abuse.
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e.g., hospi tal progress notes, laboratory reports, and diagnostics 
reports) related to the event.
The invest igator will then record all relevant AE/SAE informat ion in the CRF.
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to Sp onsor or designee in lieu of co mpletion of the AE/SAE CRF page.
There m ay be instances when copies of medical records for certain cases are requested 
by Sponsor or designee. In this case, all part icipant identifiers, with the exception o f 
the participant n umber, will be redacted on the copies of the medical records before 
submissio n to Sponsor or designee.
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the d iagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to one of the fo llowing categori es, which together with serious (i.e., 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
106SAE) criteria on the AE CRF (“results in death” and “life -threatening”), are aligned wit h the 
Divisio n of AIDS (DAIDS) Table for Grading the Severit y of Adult and Pediatric Adverse 
Events, version 2.1 (July  2017).
Mild: Mild symptoms causing no or minimal interference with usual social and functional 
activit ies, with intervention not indicated.
Moderate: Moderate symptoms causing greater than minimal interference wit h usual 
social and f uncti onal activities, with interventi on indicated.
Severe: Severe symptoms causing inabilit y to perform usual social and functional 
activit ies, with intervention or hospitalization indicated.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying dis ease(s), concomitant therapy , and other ri sk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the Invest igator’s Brochure (IB) and/or Pro duct 
Inform ation, for marketed products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to Sponsor or designee. However, it 
is very important that the investigator always make an assessment of causalit y for 
every event before the init ial transmissio n ofthe SAE data to Sponsor or designee.
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment i s one of the cri teria used whe n determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by Sponsor or 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
107designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies dur ing participation in the study or during a recognized fo llow-up 
period, the invest igator will provide Sponsor or designee with a copy o f any 
post-mortem findings including histopathology . 
New or updated informat ion will be recorded in the originally co mpleted CRF.
The invest igator will submit any updated SAE data to Sponsor or designee wit hin 24 
hours of receipt of the informat ion. 
10.3.4. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electroni c data collect ion 
tool.
If the electronic system is unavailable, then the site will use the paper SAE data 
collect ion tool  (see next secti on) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be 
taken off -line to prevent the entry  of new data or changes to exist ing data.
If a site receives a report of a new SAE fro m a study parti cipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on a paper SAE form (see next 
section) or to the sponsor by telephone.
Contact s for SAE reporting can be found in site training documents .
SAE Reporting via Paper CRF
Facsimile transmissio n of the SAE paper CRF is the preferred method to transmit this 
inform ation to the sponsor.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in site training documents .
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
108
Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy Inform ation
Women
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming post -menopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual  cycle cannot be 
confirmed before first dose of study  intervent ion, addi tional eval uation shoul d be considered.
Woman not of Childbearing Potential
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th either
a.Docum ented hysterectomy
b.Docum ented bilateral  salpingectomy , or
c.Docum ented bilateral  oophorectomy .
For individuals wit h permanent infert ility due to an alternate medical cause other than the above, 
(e.g., m ullerian agenesis, androgen insensit ivity), investigator di scret ion shoul d be applied to 
determining study  entry . 
Note: Determination can co me from the site personnel’s review of the participant’s medical 
records, medical examinat ion, or medical history  interview. 
3.Postmenopausal  female is defined a s, wom en wi th:
a.12 m onths of amenorrhea for women >55, with no need for FSH
b.12 m onths of amenorrhea for women >40 y ears o ld with FSH ≥40 m IU/mL and 
no other medical condit ion such as anorexia nervosa and not taking medicat ions 
during the amenorrhea (e.g. ,oral contraceptives, hormones, gonadotropin 
releasing hormone, ant i-estrogens, select ive estrogen receptor modulators 
(SERMs), or chemotherapy  that induced amenorrhea)
Participation in the Study
Women of child -bearing potenti al may part icipate in this study .
Women of child -bearing potenti al must test negative for pregnancy  prior to ini tiation of 
treatm ent as indicated by  a negative urine pregnancy  test at the screening visit.
Women of child -bearing potenti al who are com pletely  abstinent or in a same sex rela tionship, as 
part of their preferred and usual lifest yle, must agree to either remain abst inent or stay  in a same 
sex rel ationship wit hout sexual relat ionships with males.
All other women of child -bearing potential must agree to use two forms of effectiv e 
contraception, where at least one form is highly effective (less than 1% failure rate), for the 
entirety of the study .  
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
109Abstinence or contraception must continue for 90 days after the last dose of intervent ion.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are not 
limited to
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
Not Acceptable Methods of Contraception
Use of male and female condoms as a double barrier method is not considered acceptable due to 
the high failure rate when these barrier methods are combined. 
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not an effect ive or 
acceptable method of contraception.  
Periodic abst inence (e.g., calendar, ovulat ion, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a trial, and withdrawal are not acceptable 
methods of contraception.
Men
Men, regardless of their fertilit y status, m ust agree to ei ther remain abstinent (if this is their 
preferred and usual lifest yle) or use condoms as well as one addit ional highly effect ive method 
of contracepti on (less than 1% failure rate) or effective method of contraception with non -
pregnant women of child bearing potential partners for the duration of the study a nd until their 
plasma concentrations are below the level that could result in a relevant potential exposure to a 
possible fetus, predicted to be 90 day s after the l ast dose.
Men wi th pregnant partners should use condoms during intercourse for the duration of the study  
and until the end of est imated relevant potential exposure to the fetus, predicted to be 90 days 
after the l ast dose.
Acceptable Methods of Contraception
Highly effect ive methods of contraception (less than 1% failure rate) comprise, but are n ot 
limited to
combinat ion oral  contraceptives 
implanted con tracepti ves, or 
intrauterine devices. 
Effect ive methods of contraception comprise but are not limited to diaphragms wit h spermicide 
or cervi cal sponges.  
Men and their partners may  choose to us e a double –barrier m ethod of contraception that must 
include use of a spermicide.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
110Other Guidance
Men should refrain fro m sperm  donat ion for the durati on of  the study  and unt il their plasma 
concentrations are below the level that could result  in a relevant potential exposure to a possible 
fetus , predi cted to be 90 days after the last dose. 
Collection of Pregnancy Information
Male participants with partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male partici pant’s female 
partner who becomes pregnant while the male participant is in this study . This applies only to 
male participants who receive study  intervent ion.
After obtaining the necessary  signed informed consent and assent (if applicable) from the 
pregnan t female partner di rectly, the investigator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the partner’s 
pregnancy. 
The female partner will also be fo llowed to determine the outcome of the pregnancy . Informati on 
on the status of the mother and child will be forwarded to the sponsor. Generally, the fo llow-up 
will be no longer than 6 to 8 weeks fo llowing the estimated delivery  date. Any  terminati on of  the 
pregnancy will be reported includ ing fetal status (presence or absence of anomalies) and 
indicat ion for the procedure. 
Female Participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this study .  The init ial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning of a participant's 
pregnancy. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
will co llect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. General ly,this informat ion will include a fo llow-up of  at least 5 half -
lives after last exposure or birth . Any  terminati on of  pregnancy will be reported, including fetal 
status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for m edical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <20 weeks gestational age) or still birth (occurring a t >20 
weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study intervention 
by the investigator will be reported to the sponsor as described in S ection 8.3.4 . While the 
investigator is not obligated to actively seek this informat ion in former study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will be wi thdrawn 
from the study  and will  follow the standard discontinuat ion process.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
111
Appendix 5: Genetics
Sample collect ion informat ion is found in Appendix 2, Section 10.2 (Clinical Laboratory Tests).
Use/Analysis of DNA
Genet ic variat ion may impact a pa rticipant’s response to study  intervent ion, suscept ibilit y to, and 
severi ty and progressi on of  disease.  Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excretion; 
mechan ism of action of  the drug; di sease et iology; and/or mo lecular subt ype of the disease being 
treated.  Therefore, where local regulations and IRB/IEC allow, a blood sample will be collected 
for DNA analysis fro m consenting part icipants.
DNA samples m ay be us ed for research rel ated to SARS -CoV -2and related diseases. They may 
also be used to develop tests/assays including diagnostic tests related to LY3819253, 
LY3832479 , LY3853113, VIR-7831 or SARS -CoV -2.  Genetic research may consist of the 
analysis of one or more candidate genes or the analysis o f genet ic markers throughout the 
geno me as appropriate.
The samples may  be analyzed as part of a mult i-study  assessment of genetic factors involved in 
the response to LY3819253, LY3832479 , LY3853113, VIR-7831 or study intervent ions of this 
class to understand study  disease or related condit ions.
The results of genet ic analyses may be reported in the clinical study report (CSR) or in a separate 
study  summary .
The sponsor will store the DNA samples in a secure storage sp ace with adequate measures to 
protect confident iality.
The samples will be retained at a facilit y selected by the sponsor or its designee while research 
on SARS -CoV -2 continues but no longer than 7 years or other period as per local requirements. 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
112
Append ix 6: Recommended Laboratory Testing for 
Hypersensitivity Events.
Laboratory  assessments shoul d be perform ed if the parti cipant experiences generalized urticaria 
or if anaphylaxis is suspected.
Collect sample after the participant has been stabilized, and within 1 to 2 hours of the 
event; however, samples may be obtained as late as 12 hours after the event as analytes 
can remain altered for an extended period of time.  Record the time at which the sample 
was collected.
Obtain a fo llow-up sam ple at the next regularly scheduled visit or after approximately 4 
weeks, whichever is later.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
113Clinical Lab Tests for Hypersensitivity Events
Hypersensitivity Tests Notes
Selected test may be obtained in the event of anaphylaxis or 
systemic allergic/hypersensitivity reactions.
LY3819253 ,LY3832479 , 
LY3853113, and VIR -7831 
anti-drug antibodies 
(immunogenicity/ADA)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
LY3819253 ,LY3832479 , 
LY3853113, and VIR -7831
concentrat ions (PK)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Tryptase Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Urine N -methylhistamine testing is performed in addition to 
tryptase testing.  Collect the first void urine following the event. 
Collect a follow -up urine sample after approximately 4 weeks.
Note: If a tryptase sample is obtained more than 2 hours after the 
event (that is, within 2 to 12 ho urs), or is not obtained because more 
than 12 hours have lapsed since the event, collect a urine sample for 
N-methylhistamine testing. 
N-methylhistamine Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Drug-specific IgE Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Basophil activation test Will be performed if a validated assay is available.
Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
NOTE: The basophil activation test is an in vitro cell based assay 
that only requires a serum sample. It is a surrogate assay for drug 
specific IgE but is not specific for IgE.
Complement (C3, C3a and 
C5a)Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Cytokine panel Assayed by Lilly -designated laboratory. 
Results will not be provided to the investigative sites.
Abbreviations: ADA = anti -drug antibody; IgE = immunoglobulin E; PK = pharmacokinetic.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
114
Appendix 7: Liver Safety : Suggested Actions and Follow -up 
Assessments
Close Hepatic Monitoring
This table describes when close hepat ic monitoring shoul d occur.
If a participant with baseline results 
of ... develops the following elevations…
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN
ALP <1.5 ×ULN ALP ≥2×ULN
TBL <1.5 ×ULNTBL ≥2×ULN (except for participants with Gilbert’s 
syndrome)
ALT or AST ≥1.5×ULN ALT or AST ≥2×baseline
ALP ≥1.5×ULN ALP ≥2×baseline
TBL ≥1.5×ULNTBL ≥2×baseline (except for participants with Gilbert’s 
syndrome)
The l aboratory  tests listed in Appendix 2, including ALT, AST, ALP, TBL, direct bilirubin , 
gamma -glutamyl  transferase, and creatine kinase, should be repeated within 48 to 72 hours to 
confirm the abnormalit y and to determine whether it is increasing or decreasing.
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for the 
possible causes of the abnormal liver tests should be init iated by  the investi gator i n consul tation 
with the sponsor.
At a minimum, this evaluat ion should include a physical examinat ion and a thorough medical 
history , including symptoms, recent illnesses (for example, heart failure, systemic infect ion, 
hypotension, seizures) recent travel, history  of concomi tant m edicati ons (including over -the-
counter), herbal and dietary  supplements, history  of alcoho l use, and other substance abuse.
Initially, m onitorin g of symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tests.  
Subsequently, the frequency o f monitoring m ay be l owered to once every  1 to 2 we eks if the 
participant’s clinical condit ion and l aboratory  results stabilize.  Monitoring of ALT, AST, ALP, 
and TBL should continue unt il levels normalize or return to approximate baseline levels. 
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
115Compr ehensive Hepatic Evaluation  
A comprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
If a participant with baseline 
results of... develops the following elevations…
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN with hepatic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5 ×ULN TBL ≥2×ULN (except for participants with Gilbert’s syndrome)
ALT or AST ≥1.5×ULN ALT or AST ≥2×baseline with hepatic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5×ULN ALP ≥2×baseline
TBL ≥1.5×ULN TBL ≥1.5×baseline (except for participants with Gilbert’s syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for PT -INR; tests for viral hepat itis A, B, C, or E; tests 
for autoimmune hepatit is; and an abdominal imaging study  (for exam ple, ul trasound or CT scan). 
Based on the participant ’s history  and ini tial resul ts, further testing should be co nsidered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus 
(HDV), cy tomegalovirus (CMV), Epstein -Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxico logy screen, W ilson’s disease , blood al coho l levels, 
urinary  ethyl  glucuronide, and serum phosphat idylethano l. 
Based on the circumstances and the invest igator ’s assessment of the participant ’s clinical 
condi tion, the invest igator should consider referring the participant for a hepato logist or 
gastroenterologist consultation, magnet ic resonance cho langiopancreatography  (MRCP), 
endoscopi c retrograde cholangiopancreatography  (ERCP), cardi ac echocardi ogram , or a liver 
biopsy .  
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
116Additional Hepatic Data Collection (Hepatic Safety CRF) 
Additional hepatic safety data collection in hepatic safety case report forms (CRF) should be performed in 
study participants who either have a hepatic event considered to be an SAE or meet 1 or more of these 
conditions:
If a participant with baseline... hasthe following elevations…
ALT <1.5 ×ULN ALT ≥5 × ULN on 2 or more consecutive blood tests 
ALP <1.5 × ULN ALP ≥2 × ULN on 2 or more consecutive blood tests
TBL <1.5 × ULN TBL ≥2 × ULN, except for cases of known Gilbert’s syndrome
ALT ≥1.5 × ULN ALT ≥3 × baseline on 2 or more consecutive blood tests
ALP ≥1.5 × ULN ALP ≥2 × baseline on 2 or more consecutive blood tests
TBL ≥1.5 × ULN TBL ≥2 × baseline
Abbreviations:  ALP =alkaline phosphatase; ALT =alanine aminotransferase; AST = aspartate
aminotransferase; TBL =total bilirubin; ULN =upper limit of normal.
Note:  The interval between the 2 consecutive blood tests should be at least 2 days.
Hepatic Evaluation Testing
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except 
for microbi ology testing.
Local  testing m ay be performed in addit ion to central testing when necessary for immediate 
participant m anagement.
Results will be reported if a validated test or calculation is available.
Hematology Clini cal Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    Monocytes Other Chemistry
    Basophils Acetaminophen
    Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
Coagulation Copper
Ethyl alcohol (EtOH)
Prothrombin time, INR (PT -INR) Haptoglobin
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
117Serology Immunoglobulin IgA (quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
    HAV total antibody Immunoglobulin IgM (quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing: Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc) Other Serology
    Hepatitis B core IgM antibody Anti-nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
    HBV DNA b Anti-actin antibody c
Hepatis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA b     EBV DNA b
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA b
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNA b     HSV (Type 1 and 2) DNA b
Microbiology d Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
a
Not required if anti -actin antibody is tested.
bReflex/confirmation dependent on regulatory requirements, testing availability, or both.
cNot required if anti -smooth muscle antibody (ASMA) is tested.
dAssay ed ONLY by investigator -designated local laboratory; no central testing available.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
118
Appendix 8: Abbreviations
Term Definition
AC assessment committee
ADA anti-drug antibody
ADE antibody -dependent enhancement
assent Agreement from a child or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and potential risks involved in 
participating in a study.
blinding/masking A single -blind study is one in which the investigator and/or his staff ar e aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A double -blind study is one in which neither the participant nor any of the in vestigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the 
participants are aware of the treatment received.
CIOMS Council forInternational Organizations ofMedical Sciences
Com plaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of an intervention.
Com pliance Adherence to all study -related, good clinical practice (G CP), and applicable regulatory 
requirements.
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
DMC data monitoring committee
ECG Electrocardiogram
FiO2 fraction of inspired oxygen 
Enroll The act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.
Enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
GCP good clinical practice
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
119IgG1 Immunoglobulin G1
IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by means of a written, signed and dated informed consent form .
interim analysis An interim analysis is an analysis of clin ical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
Intervention A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, inclu ding products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the autho rized form.
IWRS interactive web -response sy stem
mAb monoclonal antibody
NP Nasophary ngeal
Participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PK/PD pharmacokinetics/pharmacodynamics
SAE serious adverse event
SAP statistical analysis plan
Screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SpO2 saturatio n of peripheral oxygen
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
120
Appendix 9: Protocol Amendment Histor y
Amendment f 16 March 2021
Overall Rationale for the Amendment:
The purpose of this amendment is to incorporate a new study  intervent ion, LY3853113, into the 
study  design.
Section # and Name Description of Change Brief Rationale
1.1 Synopsis; 1.2 Schema; 1.3 Schedule of 
Activities; 3 Objectives and Endpoints; 4.1 
Overall Design; 4.2 Scientific Rationale for 
Study Design; 6.1 Study Intervention(s) 
Administered; 8.1 Efficacy Assessments; 
8.4 Treatment of Overdose; 8.5 
Pharmacokinetics; 8.5.1 Bioanalytical; 8.6 
Pharmacodynamics; 8.8 Biomarkers; 8.9 
Immunogenicity Assessments; 10 .2 
Appendix 2: Clinical Laboratory Tests; 10.5 
Appendix 5: Genetics; 10.6 Appendix 6: 
Recommended Laboratory Testing for 
Hypersensitivity EventsAdded Arms 9-13to study 
design; updated language 
throughout protocol to include 
LY3853113.Arms added to incorpora te new 
study intervention 
(LY3853113 ) into design; 
language updated throughout to 
align with the addition of 
LY3853113
1.1 Synopsis; 2 Introduction ; 2.1 Study 
Rationale; 2.2 Background; 2.3 
Benefit/Risk AssessmentProvided background 
information for LY385 3113Updated section to include 
information about LY3853113
2.2 Background Updated LY3819253+ 
LY3832479 safety informationUpdated to provide more recent 
safety information
4.3 Justification for Dose Added justification for 
LY3853113 + LY3819253 + 
LY3832479 combinationUpdated to provide justification 
for LY3853113
5.1 Inclusion Criteria; 5.2 Exclusion 
Criteria; 10.1.3 Informed Consent ProcessAdded specifications for low or 
high-risk participants; 
expanded participant 
popul ation to include 
adolescentsAlignment with updated study 
design
5.1 Inclusion CriteriaCriterio n 3: Updated list of 
COVID -19 sy mptomsUpdated list to align with 
current guidance
5.1 Inclusion Criteria ; Appendix 4: 
Contraceptive Guidance and Collection of 
Pregnancy InformationCriterio n 5: Clarified provision 
of reproductive and 
contraceptive agreements and 
guidance in Appendix 4Clarification
5.2 Exclusion Criteria Added Criterion 29Alignment with updated study 
design
6.3 Measures to Minimize Bias: 
Randomization and BlindingAdded stratification factors for 
arms 12 -13; specified blinding 
for arms 1 -11.Alignment with updated study 
design
6.5 Concomitant TherapyAdded statement clarifying that 
prior SARS -CoV-2 vaccines 
should be recordedClarification
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
121Section # and Name Description of Change Brief Rationale
8.2.2 Vital SignsAdded new tables for Arms 9 -
11, 13Alignment with updated study 
design
9.1 Statis tical Hyp otheses; 9.2 Sample Size 
Determination; 9.4 Statistical Analyses; 
9.4.2 Primary Endpoints; 9.4.3.1 Safety 
(arms 1 -11); 9.4.3.2 Additional Secondary 
Endpoints ; 9.4.3.3 Pharmacokinetic 
Analy ses; 9.4.5 Immunogenicity AnalysesUpdated statistical 
considerations to incorporate 
LY3853113 into study designAlignment with updated study 
design
ThroughoutMinor editorial and formatting 
changesMinor, therefore not detailed
Amendment e 25 January 2021
Overall Rationale for the Amendment:
The purpose of this amendment is to include a new fo llow-up phone visit for Arms 7 and 8 to 
assess for the occurrence of any safet y concerns. Addit ionally , the am endment incorporates new 
background informat ion for VIR -7831 and updates the benefit/risk language of LY3819253.
Section # and Name Description of Change Brief Rationale
1.1 Synopsis;
1.3.2. Treatment Arms 7 -8;
4.1.1. Design Outline;
4.2. Scientific Rationale for Study Design
7.1. Discontinuation of Study InterventionAdded Day 169 timepoint with 
AE collection and concomitant 
medicationsAdded to assess for occurrence 
of any safety concerns for 
Arms 7 and 8
2.2. BackgroundUpdated background 
information for VIR -7831Included most up to date 
information on VIR -7831 f rom 
ongoing clinical trials
2.3. Benefit/Risk AssessmentRevised language regarding 
clinical worsening of COVID -
19 sy mptoms after LY3819253 
administrationAlignment with bamlanivim ab 
EUA Fact Sheet
ThroughoutMinor editorial and formatting 
changesMinor, therefore not detailed
Amendment d 15 January 2021
Overall Rationale for the Amendment:
The purpose of this amendment is to rem ove pregnant wom en from the study  popul ation.
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
122Secti on # and Name Description of Change Brief Rationale
2.3 Benefit/Risk Assessment; 4.2 Scientific 
Rationale for Study Design; 5.1 Inclusion 
Criteria; 5.2 Exclusion Criteria; 7.2 
Participant Discontinuation/Withdrawal 
from the Study; 8.2.3 Clinical Laboratory 
Assessments; Appendix 4: Contraceptive 
Guidance and Collection of Pregnancy 
Information; 11 ReferencesRem oval of pregnant women 
from study populationResponse to IRB feedback
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
123Amendment c 06 January 2021
Overall Rationale for the Amendment:
The purpose of this amendment is to incorporate a new study  intervent ion, VIR -7831, into the 
study  design.
Section # and Name Description of Change Brief Rationale
1.1 Synopsis ; 1.2 Schema; 1.3 Schedule of 
Activities; 3 Objectives and Endpoints ; 4.1 
Overa ll Design; 4.2 Scientific Rationale for 
Study Design; 6.1 Study Intervention(s) 
Administered ; 8.1 Efficacy Assessments ; 
8.4 Treatment of Overdose; 8.5 
Pharmacokinetics ; 8.5.1 Bioanalytical; 8.6 
Pharmacodynamics; 8.8 Biomarkers ; 8.9 
Immunogenicity Assessmen ts; 10.2 
Appendix 2: Clinical Laboratory Tests; 10.6 
Appendix 6: Recommended Laboratory 
Testing for Hypersensitivity EventsAdded Arms 7 , 8, and 9 to 
study design; updated language 
throughout protocol to include 
VIR-7831Arms added to incorporate new 
study intervention (VIR -7831) 
into design; language updated 
throughout to align with the 
addition of VIR -7831
1.3 Synopsis; 3 Objectives and Endpoints ; 
9.4.3.2 Additional Secondary EndpointsRem oved Day22 from 
proportion of participants that 
achieve SARS -CoV-2 
clearanceNo NP swab collection on Day 
22
1.1 Synopsis; 2 Introduction ; 2.1 Study 
Rationale; 2.2 Background; 2.3 
Benefit/Risk AssessmentUpdated background 
information for VIR -7831Updated to include information 
about VIR -7831
4.3 Justification for Dose Added justification for 
LY3819253 + VIR -7831 
combinatio nUpdated to provide justification 
for VIR -7831
5.1 Inclusion criteria ; 5.2 E xclusion criteria; 
8.2.3 Clinical Laboratory Assessments;
8.3.5 Pregnancy; 10.4 Appendix 4: 
Contrace ptive Guidance and Collection of 
Pregnancy InformationUpdated study population to 
include pregnant womenIncluding due to potential 
favorable benefit/risk 
assessment for high -risk group
9.1 Statis tical Hyp otheses; 9.2 Sample Size 
Determination; 9.4.3.2 A dditional 
Secondary Endpoints ; 9.5 Interim AnalysesUpdated statistical 
considerations to incorporate 
VIR-7831 into study designUpdated to align with amended 
study design
Throughout Minor editorial and formatting 
changesMinor, therefore not detailed
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
124Amendment b 03 December 2020
Overall Rationale for the Amendment:
The purpose of this amendment is to incorporate a new treatment arm (Arm 6) into the study  
design. Addit ionally, minor administrative changes and clarificat ions have been made to the 
Schedu le of Act ivities and Secondary  Object ives and Endpo ints.
Section # and Name Description of Change Brief Rationale
1.1 Synopsis; 1.2 Schema; 
4.1.1 Design Outline; 6.1 
Study  Intervent ion(s) 
Administered; 9.2 Sample Size 
Determinat ionAdded treatm ent arm  6 to 
study; specified approximate 
number of participants to be 
enrolled into arms 3 and 6Added to explore new 
dose l evel in study .
1.1 Synopsis; 3 Object ives and 
Endpoints; 6.1 Study  
Intervention(s) Administered; 
9.4.3.2 Addit ional Secondary  
EndpointsModi fied secondary  endpoints 
for symptom  resol ution, 
symptom  improvement, SARS -
CoV -2 viral load, and SARS -
CoV -2 clearanceModified for consistency  
with other secondary  
endpo ints
1.3 Schedule of Act ivities Modified Day  11 visi t window Administrative
6.1 Study  Intervention(s) 
AdministeredChanged ‘pharmacy manual’ to 
‘pharmacy  preparat ion 
instructi ons’Administrative
6.3 Measures to Minimize 
Bias: Randomizat ion and 
BlindingAdded language clarifying 
staggered enrollment of 
participantsClarificat ion
9.1 Statist ical Hypotheses Updated hy pothesis to i nclude 
arm 6Modificat ions made to 
align with updated study  
design
9.5 Interim Analyses Provi ded details of addit ional 
interim analysisAdded to align with 
updated study  design
Throughout Minor edi torial changes Minor, therefore not 
detailed
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
125Amendment a: 16 October 2020
Overall Rationale for the Amendment:
This amendment modifies the secondary endpoints that measure clinical events (deaths, hospitalizations, 
and ER visits) to include events through Day 29, in response to FDA feedback.
Section # and Name Description of Change Brief Rationale
Secti on 1.1 
Synopsis
Secti on 3 
Object ives and 
Endpoints
Secti on 9.4.3.2 
Addit ional
Secondary  
EndpointsAdded Day 29 to clinical 
events secondary  endpoints FDA Feedback
Throughout the 
protocolMinor edi torial changes Minor, therefore not described
CONFIDENTIAL Protocol J2X-MC-PYAH (g)
12611. References
Aoki FY, Macleod MD, Paggiaro P, Carewicz A, El Sawy A, Wat C, Griffiths M, Waalberg E, 
Ward P on behalf of the IMPACT Study  Group. Early  administrati on of  oral oseltamivir 
increases the benefit s of influenza treatment. J. Antimicrob Chemother. January  2003:123 -129.
https:// doi.org/10.1093/jac/dkg007.
CDC clinical growth charts .  National Center for Health Statist ics, Clinical Growth Charts.  
Centers for Disease Control and Prevent ion web site.  Available at: https://
www.cdc.gov/growthcharts/clinical_charts.htm. June 2017 . Accessed:16 March 2021.
[CDC] Centers for Disease Control and Prevent ion. COVID -19 in children and teens. 
Inform ation for parents and caregivers about COVID -19 in children and teens. Website page 
last updated December 18, 2020. Accessed March 16, 2021. Available at: 
https://www.cdc.gov/coronavirus/2019 -ncov/daily -life-coping/children/symptoms.html .
[CDC] Centers for Disease Control and Prev ention. Peopl e at increased risk and other people 
who need to take extra precautions. Updated March 15, 2021 . Accessed March 16, 2021. 
https://www.cdc.gov/coronavirus/2019 -ncov/need -extra -
precauti ons/index.ht ml?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%
2F2019 -ncov%2Fneed -extra -precauti ons%2Fpeople -at-increased -risk.ht ml.
[CDC] Centers for Disease Control and Prevent ion. US COVID -19 cases caused by variants. 
Updated February  21, 2021. Accessed March 16 , 2021. 
https://www.cdc.gov/coronavirus/2019 -ncov/transmissio n/variant -cases.ht ml.
Divisio n of AIDS (DAIDS) Table for Grading the Severit y of Adult and Pediatric Adverse 
Events. National Inst itute of Allergy and Infect ious Di seases. Nati onal Insti tutes of Heal th. US 
Departm ent of Healt h and Human Services. Corrected version 2.1. July 2017. Available at: 
https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf . Accessed: 05 
October 2020.
FDA resource page. COVID -19: Developing Drugs and Bio logical  Products for Treatm ent or 
Prevent ion Guidance for Industry . Food and Drug Administration web site. Available at: 
https:// www.fda.gov/regulatory -informat ion/search -fda-guidance -docum ents/covid -19-
developing -drugs -and-biological -products -treatm ent-or-prevent ion. Accessed 12March 2021.
Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L. Clinical features and progression o f acute 
respi ratory  distress syndrome in coronavirus disease 2019. medRxiv. Posted 27 February
2020. preprint DOI : https:// doi.org/10.1101/2020.02.17.20024166 . 
Leo Document ID = 75f8c245-a194-48ae-8def-5381f1ee605b
Approval Date & Time: 17-May-2021 19:49:29 GMT
Signature meaning: Approved
Approval Date & Time: 18-May-2021 00:09:34 GMT
Signature meaning: Approved
PPD
PPD